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DEVELOPMENT OF QUANTITATIVE MOLECULAR PHOTOACOUSTIC IMAGING
FOR NONINVASIVE CANCER DIAGNOSTICS

Cayla A. W. Zandbergen, M.S.

Advisory Professor: Richard R. Bouchard, Ph.D.

Traditional diagnostic imaging provides clinicians with anatomical information that guides
both diagnosis and treatment planning; however, once a tumor has progressed enough to
be visible, it has often reached an advanced stage. Molecular imaging techniques allow for
real-time visualization of chemical and biological processes via imaging of specific biomarkers, which can facilitate detection of malignancies before they become visible. One biomarker
of interest is blood oxygen saturation (SO2 ) due to its correlation with hypoxia, which is associated with increased tumor malignancy; some studies have also established SO2 as an
independent biomarker of disease progression. Additionally, because cancerous cells commonly overexpress specific antigens (e.g., folate receptor alpha [FRα] in ovarian cancer), cell
receptor expression is an emerging biomarker that can be leveraged to localize malignant
cells and guide patient-specific treatment strategies. Molecular imaging strategies are being
explored to assess these biomarkers; however, each suffers from inherent limitations, such
as poor spatiotemporal resolution, poor depth penetration, or high regulation from the use of
ionizing radiation.
To overcome these challenges, photoacoustic (PA) imaging is being investigated due to
its sensitivity to nano-sized optical contrast at clinically relevant depths with high spatiotemporal resolution. In this work, multi-wavelength PA imaging techniques were developed for
noninvasive, quantitative visualization of two biomarkers: SO2 , via imaging of oxy- and deoxyvii

hemoglobin; and cell receptor expression, via imaging of a novel contrast agent, liposomeencapsulated J-aggregated indocyanine green (Lipo-JICG), which is conjugated with anti-FRα
antibodies for specific targeting to the FRα receptor on ovarian cancer cells. SO2 was shown
to have potential as a biomarker in disease progression of acute lymphoblastic leukemia, with
significantly more change in SO2 (relative to individual baseline) in diseased than in control
mice. Lipo-JICG was first characterized in phantom environments, demonstrating its ability for
simultaneous imaging and unmixing with endogenous hemoglobin (allowing for more straightforward in vivo imaging) and its fluence and photothermal stability during PA imaging. Specificity of Lipo-JICG targeting was also shown in vitro, with more signal from SKOV3 cells (i.e.,
high FRα expression), as well as in vivo, with increased Lipo-JICG contrast enhancement observed from targeted FRα-Lipo-JICG than non-targeted RG-16-Lipo-JICG in mice with SKOV3
ovarian tumors.
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Chapter 1: Introduction
1.1 Significance
Traditionally, clinical diagnostic imaging provides oncologists with anatomical information that
guides both diagnosis and treatment planning. However, once a tumor has progressed enough
to be visible with imaging, it has often reached a more advanced stage. To supplement this
diagnostic information, molecular imaging techniques have emerged, both clinically and preclinically. Molecular imaging is becoming a key tool in both diagnostics and therapy with the
emergence of patient-specific treatment schemes to allow for real-time visualization of chemical and biological processes, bridging the gap between traditional in vivo anatomical imaging
and ex vivo histopathology [1]. Currently, the only widespread clinical molecular imaging technique is positron emission tomography (PET), which is incredibly sensitive with only trace
amounts of radionuclide injections required to achieve high imaging contrast, but has relatively
poor spatial resolution and is highly regulated due to its use of ionizing radiation [2, 3].
Of the clinically viable molecular imaging strategies being explored preclinically, photoacoustic (PA) imaging is one of the most promising, making inroads into the clinic due to its
non-ionizing nature and ability to resolve optical contrast at a clinically relevant depths with
high spatiotemporal resolution [4, 5]. PA imaging has shown encouraging clinical potential using endogenous hemoglobin (i.e., oxy- and deoxyhemoglobin [HbO2 & HHb]) to assess blood
oxygen saturation (SO2 ), an emerging biomarker for many diseases [6–8]. Additionally, a
variety of exogenous contrast agents (e.g., gold nanoparticles [AuNPs] [9] and optically absorbing dyes [10, 11]) have shown preclinical potential for molecular imaging of cell-specific
markers, allowing for identification of certain cell types in vivo. Because PA imaging systems
often use a conventional pulse-echo ultrasound (US) transducer, PA images can be inherently
co-registered with B-mode US images, providing an anatomical reference with functional information [12]. Through concurrent PA-US imaging, it is possible to achieve high-resolution
1

anatomical and molecular imaging at depth with both endogenous and exogenous contrast.

1.2 Objectives and Hypothesis
The long-term goal of this project is to develop and optimize a PA imaging platform for noninvasive, quantitative, in vivo visualization of imaging biomarkers. Interactions between malignant
cancerous cells and the tumor microenvironment can provide insight into disease progression
and eventually inform patient-specific treatment options [13]. To visualize these interactions
noninvasively, this work investigates PA imaging of two imaging biomarkers: SO2 , which has
been shown to be a biomarker for disease progression in multiple preclinical studies [14–17];
and cell receptor expression, which is indicative of disease progression and treatment response in many cancer subtypes [18–21]. The central hypothesis is that multi-wavelength
PA imaging of clinically relevant endogenous and exogenous absorbers will provide
translatable functional and molecular imaging with high sensitivity and specificity for
noninvasive, longitudinal monitoring of disease progression of cancer.

1.3 Specific Aims
To test the central hypothesis, we have developed the following specific aims:
Specific Aim 1: Characterize and validate spectral PA imaging methods for accurate visualization and assessment of endogenous and exogenous agents in phantoms.
Subaim 1.1: Characterize liposome-encapsulated J-aggregated indocyanine green (LipoJICG) particles.
Subaim 1.2: Image tissue-mimicking gelatin phantoms with blood and Lipo-JICG samples in embedded polyethylene (PE) tube.
Specific Aim 2: Correlate PA-based assessment of hemoglobin with disease progression in
a preclinical model of acute lymphoblastic leukemia.

2

Subaim 2.1: Optimize and validate PA imaging parameters for femoral bone marrow
imaging.
Subaim 2.2: Validate longitudinal PA imaging in wild-type mice and compare to PAbased SO2 estimates in leukemic mice over time.
Specific Aim 3: Correlate PA-based assessment of endogenous and exogenous agents with
disease progression in a preclinical model of ovarian cancer.
Subaim 3.1: Optimize and validate Lipo-JICG for in vivo biosafety and PA imaging.
Subaim 3.2: Compare targeted (FRα) and non-targeted (RG-16) Lipo-JICG in preclinical
ovarian model at multiple time-points.

1.4 Dissertation Organization
This dissertation is organized as follows: Chapter 2 provides background information on the
tumor microenvironment and key imaging biomarkers as well as PA imaging. Chapter 3 details
Specific Aim 1 and presents the results of Lipo-JICG characterization in phantom environments. Chapter 4 provides Specific Aim 2 and details the assessment of SO2 in a preclinical
model of ALL. Chapter 5 addresses Specific Aim 3, including fluence correction for more accurate PA quantification in a preclinical model of ovarian cancer. Finally, Chapter 6 summarizes
the dissertation and provides possible future avenues for this work.

3

Chapter 2: Background
2.1 Introduction
Some sections of this chapter are adapted from introductory sections of the following published
works:
Reprinted, with permission, from C. Wood, K. Harutyunyan, D. Sampaio, M. Konopleva,
R. Bouchard. Photoacoustic-based oxygen saturation assessment of murine femoral bone
marrow in a preclinical model of leukemia. Photoacoustics, 14:31-36, 2019. Open Access
License CC BY-NC-ND 4.0.
Reprinted, with permission, from M. Naser, D. Sampaio, N. Munoz, C. Wood, T. Mitcham,
W. Stefan, K. Sokolov, T. Pavan, R. Avritscher, R. Bouchard. Improved Photoacoustic-Based
Oxygen Saturation Estimation With SNR-Regularized Local Fluence Correction. IEEE Transactions on Medical Imaging, 38(2):561-571, 2019.
All other content is original and unpublished at the time of the submission of this work
unless specified otherwise.

2.2 Rationale
As tumors grow, they develop a complex network, known as the tumor microenvironment (Figure 2.1). This consists of not only malignant and normal cells, but also immune cells, signaling
molecules, and a complex extracellular matrix (ECM), which often have common features independent of the tumor type and site [22–24]. Because interactions between malignant cells and
the tumor microenvironment dictate disease progression, gaining insight into these interactions
can not only improve diagnosis but also provide more patient-specific treatment options [13].
To inform these treatment strategies, it is necessary to provide physicians with noninvasive
visualization of tumor microenvironment interactions, which is mediated by molecular imaging
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of specific biomarkers [25]. Some imaging biomarkers in the tumor microenvironment include
ECM proteins, cell signaling proteins, angiogenesis, hypoxia, and extracellular pH [2]. In this
work, we will investigate two independent biomarkers to map these tumor microenvironment
characteristics: blood oxygen saturation and cell receptor expression.

Figure 2.1: Tumor Microenvironment. Malignant tumor cells are supported by structural
cells as well as a variety of immune cells, forming a complex tumor microenvironment. This
supports tumor growth by enabling malignant cancerous cells to avoid immune surveillance,
evading destruction by the host body’s immune system. Image courtesy of [23], reprinted
under Open Access License CC BY 4.0.

2.2.1 Blood Oxygen Saturation
Tissue hypoxia (Figure 2.2), defined as regions in tissue with low oxygen concentration, can
be caused by a variety of factors, including low arterial oxygen partial pressure (pO2 ), anemia,
reduced tissue perfusion, increased oxygen diffusion distances, and the inability of cells to use
oxygen [26]. Hypoxia in the tumor microenvironment, which is observed in 50-60% of solid
tumors, is associated with not only increased malignancy and accelerated tumor growth, but
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with resistance to most common therapy schemes as well (i.e., radiotherapy, chemotherapy,
& immunotherapy) [27–29]. Due to this therapeutic resistance, a direct assessment of tissue
hypoxia would be useful for both cancer diagnosis and therapy [30–33]. Therefore, developing
an imaging biomarker that correlates with tumor hypoxia would be beneficial for improving the
diagnosis and treatment response for multiple types of cancer [4].

Figure 2.2: Tissue hypoxia. In the tumor microenvironment, hypoxia has been shown to
cause increased tumor growth and malignancy. Hypoxia can be caused by a number of different factors and commonly leads to therapeutic resistance. Image courtesy of [34], reprinted
under Open Access License CC BY 4.0.
The most direct method to assess tissue hypoxia in vivo is to use fiber-optic fluorescence
probes or polarographic electrodes to measure pO2 , which has been shown to correlate with
extracellular hypoxia [35]. Such instruments, however, are limited to invasive point measurements, which can affect tissue physiology and provide only a time-averaged value for a single
sampling location [36]. Preclinical methods to detect intracellular hypoxia include histological
techniques (e.g., pimonidazole immunohistochemistry) and multiphoton intravital microscopy
to probe carbonic anhydrase IX, a direct HIF-1α target [37, 38]. However, these techniques
require an exogenous agent and are generally limited to sampling a single time-point [39]. Diffuse optical tomography (DOT) has shown promise in imaging hemoglobin concentration and
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oxygenation state, but its poor spatial resolution restricts its ability to image the heterogeneity
of intratumoral oxygenation levels [40, 41].
Current clinical methods to probe hypoxia include (18 F-FAZA)-PET imaging, BOLD-MRI,
TOLD-MRI, and

19 F-MRI.

(18 F-FAZA)-PET imaging has shown correlation with hypoxia im-

munostaining [42]; however, it requires injection of a radiotracer and suffers from inherently
poor spatiotemporal resolution. BOLD-MRI is a label-free technique that suffers from quantitation issues, particularly at tissue-bone interfaces, due to susceptibility artifacts [43, 44].
Although not affected by such artifacts, TOLD-MRI’s limited sensitivity has failed to provide
substantial signal change in multiple cancer types [45, 46].

19 F-MRI

requires a perfluorocar-

bon exogenous reporter and additional imaging equipment that is not standard on an MRI
scanner to generate dynamic pO2 maps [47, 48]. To date, there is no established method for
in vivo, label-free, noninvasive, quantitative imaging of tissue oxygenation.
Because a direct measurement of pO2 is difficult to achieve noninvasively, it may be possible to use blood oxygen saturation (SO2 ) as a surrogate biomarker. Although SO2 (i.e.,
the ratio of oxyhemoglobin [HbO2 ] to total hemoglobin) is not a direct measure of tissue hypoxia, it has been shown to be correlated with pimonidazole-assessed hypoxia and pO2 levels
proximal to capillaries [49, 50], and it has also been shown as an independent biomarker for
disease progression [16]. Additionally, it can be probed with optical modalities as HbO2 and
deoxyhemoglobin (HHb) have different optical absorption spectra, allowing for a noninvasive
assessment of SO2 [51]. SO2 is calculated as

SO2 =

cHbO2
,
cHbO2 + cHHb

where cHbO2 and cHHb are the concentrations of HbO2 and HHb, respectively [51].
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(2.1)

2.2.2 Cell Receptor Expression
Cell receptors are transmembrane proteins on the surface of the cell that are responsible for
communication with other cells in the body [52]. Each cell receptor accepts a specific signaling
molecule, which then causes a physiological response within the cell [53]. In the case of cancerous cells, a specific antigen is commonly overexpressed by the cell, which has led to the
development of antigen-specific targeting strategies for both imaging and therapy (Figure 2.3)
[54]. Normally, native monoclonal antibodies bind to an antigen, marking it for destruction
by the immune system. Antibody targeting leverages this phenomenon by attaching a monoclonal antibody to the imaging or therapeutic agent, delivering the agent specifically to the
cell expressing the antigen [55]. In therapy, this spares normal tissue toxicity by delivering the
therapeutic agent preferentially to cancerous cells; in imaging, it allows for the identification of
cancerous cells, providing specific molecular information about the tumor [18, 19].
In many cases, the molecular information provided by cell receptor expression is also prognostic for overall survival and therapeutic response. For example, folate receptor alpha (FRα)
is overexpressed in a variety of cancer types, including ovarian, breast, and lung cancers
[20]. In ovarian cancer, it is overexpressed in more than half of high-grade ovarian tumors,
indicating the need for more aggressive treatment [21]. Currently, the standard of treatment
for high-grade ovarian cancer is surgical resection of the primary tumor, followed by adjuvant
chemotherapy; however, in candidates where surgical resection is not likely to be successful,
it is recommended that patients undergo neoadjuvant therapy before surgery [56]. Localization of FRα can indicate the need for neoadjuvant therapy; however, the current standard for
identification of FRα is histological evaluation following a biopsy, which only samples a small
region of the tumor, making it more likely that the FRα receptor will not be present in the sample volume [57]. To better direct patients toward treatment schemes specific to their cancer
subtype, there is an unmet need for a noninvasive, quantitative, molecular imaging method to
visualize heterogeneous cell receptor expression in vivo.
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Figure 2.3: Cell Receptor Expression. In cancerous cells, specific receptors are commonly
overexpressed relative to normal cells. This can be leveraged for both imaging and therapy
by attaching an imaging biomarker or therapeutic agent to the ligand specific to that receptor,
which will then be preferentially taken up by tumor cells. Image courtesy of [21], reprinted
under Open Access License CC BY 3.0.
Currently, the only widespread clinical molecular imaging techniques are PET and SPECT,
which are incredibly sensitive with only trace amounts of radionuclide injections required to
achieve high imaging contrast, but have relatively poor spatial resolution and is highly regulated
due to its use of ionizing radiation [2, 3]. MRI-mediated techniques, such as hyperpolarized
MRI, are also being investigated for molecular imaging, both preclinically and in emerging clinical applications. Although hyperpolarized MRI allows for noninvasive imaging of metabolic and
physiologic processes, the signal decays rapidly, which necessitates a decrease in spatial resolution to acquire the images with sufficient temporal resolution [1, 58]. Optical methods, such
as bioluminescence imaging (BLI), are used preclinically for rapid, highly sensitive molecular
imaging; however, due to the inherent depth limitations of optical imaging techniques, spatial
resolution is limited and the images are typically non-quantitative, severely limiting the potential
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for clinical translation [1, 2]. Of the clinically viable molecular imaging strategies being explored
preclinically, photoacoustic (PA) imaging is one of the most promising, making inroads into the
clinic due to its non-ionizing nature and ability to resolve optical contrast at a clinically relevant
depths with high spatiotemporal resolution [4, 5].

2.3 Photoacoustic Imaging
PA imaging is a promising modality that is non-ionizing, low-cost, and offers high contrast and
high spatiotemporal resolution in an imaging platform that is amenable for high-throughput
preclinical use and for specific clinical applications (e.g., endoscopy) [4, 59]. In PA imaging, tissue is irradiated with nanosecond pulses of low-energy laser light. Optically-absorbing
chromophores in the tissue absorb the light, causing local thermal expansion, which in turn
generates acoustic waves that are then detected and spatially resolved with an ultrasound
(US) array (Figure 2.4). This results in an image related to the local optical absorption, with
penetration depth on the order of centimeters, sub-millimeter (as low as 30 µm) spatial resolution, and real-time imaging capabilities [60]. Additionally, combined PA-US imaging can be
employed to concurrently assess anatomy (i.e., with B-mode US) with inherently co-registered
PA molecular images.
From the PA wave equation, the initial pressure (p0 ) generated by a PA source can be
estimated by [12]

p0 (r, λ) =

βc2
· µa · F = Γ · µa (r, λ) · F (r, λ),
Cp

(2.2)

where β [K-1 ] is the thermal coefficient of volume expansion; c [m s-1 ] is the speed of sound
through the medium; Cp [J kg-1 K-1 ] is the heat capacity at constant pressure; µa [cm-1 ] is
the optical absorption coefficient; F [J cm-2 ] is the local laser fluence; and Γ is the unitless
Grüneisen coefficient, which indicates how well a medium is able to convert thermal energy
(i.e., absorbed light) into mechanical energy (i.e., acoustic pressure). In this work, Γ is as-
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Figure 2.4: PA Imaging. In PA imaging, tissue is irradiated with low-energy laser light. Chromophores in the tissue absorb the light and undergo local thermal expansion, generating
acoustic waves, which are detected with an US transducer. Images are acquired over multiple wavelengths, and chromophores are identified via linear unmixing of the multi-wavelength
images using the optical absorption spectra of each chromophore.
sumed to be spatially invariant in biological tissue, although this assumption is not always valid
[61].

2.3.1 Multi-Wavelength PA Imaging
Biological tissue is made up of different amounts of absorbing chromophores (e.g., hemoglobin,
lipids, and melanin), each of which has its own unique optical absorption spectrum [62]. Additionally, exogenous chromophores, such as gold nanoparticles (AuNPs) or optically absorbing
dyes, can be injected and imaged in the tissue(s) of interest. To map the location of each
of these chromophores in PA imaging data, images are acquired over multiple wavelengths,

11

which typically correspond to spectral features in the optical absorption spectra of each chromophore. Then, PA images are linearly unmixed voxel-wise to determine the relative concentrations of each absorber [63].

2.3.2 PA Assumptions
In a typical linear unmixing strategy, it is assumed that the PA signal is directly proportional
to optical absorption. However, as light propagates through the tissue, it is also scattered,
resulting in different fluences of light reaching the tissue over depth (known as spectral coloring). As a result, accurate estimation of chromophores with quantitative PA imaging is not
straightforward due to this dependence on local fluence and its often poor signal-to-noise ratio
(SNR), particularly at depth [64]. Estimation of local fluence distributions requires solving an
ill-posed inverse problem with a large number of unknown and heterogeneous tissue properties and a non-unique solution (i.e., absorption-scattering non-uniqueness) [51]. Additionally,
spectroscopic PA data tend to be signal-limited at depth (i.e., >1 cm) due to the exponential
decay of fluence that occurs in turbid tissues. Consequently, utilization of poor-SNR spectroscopic PA data can result in significant noise bias when estimating chromophore distributions.
In fact, noise can be a dominant contribution in large portions of the image - particularly for
deeper-lying voxels - and thus lead to erroneous chromophore quantifications.
There are a number of methods that have been proposed and validated (to varying extents)
for the purpose of quantitative PA imaging, which generally involves optical and acoustical
inversion problems to obtain estimates of absolute distributions of absorber concentrations
[51]. However, in the specific case of SO2 estimation considered here, only relative absorber
concentrations are needed, and thus reconstructed PA image intensity is often assumed to be
proportional to initial pressure through a single constant, obviating the need for an acoustical
inversion step. Consequently, the primary focus for inversion becomes modeling the effects of
spectral coloring through pixel-wise normalization of data by wavelength-dependent fluence,
which directly impacts PA image intensity.
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If only relative concentrations are needed and local fluence is assumed constant or just proportional to measured laser-pulse energy, then the simplest and most commonplace method
for absorber estimation is linear inversion, which is typically straightforward to solve with matrix
inversion [65, 66]. If light propagation in the medium is modeled analytically with the radiative
transfer equation (RTE), it is possible to implement direct inversion methods [67, 68]. For relatively homogeneous [59] or superficial imaging [69] (e.g., PA microscopy), an analytical model
for local fluence correction can be used. However, such an approach is often intractable for
heterogeneous media, in which case numerical modeling (e.g., Monte Carlo methods [70–72]
or finite element methods [FEMs] using the diffusion approximation of the RTE [73]) can provide accurate local fluence estimation based on heterogeneous optical properties and an arbitrary photon-source distribution. Modeled optical properties can be based entirely on a priori
assumptions (e.g., values from the literature) or on supplemental information from other modalities, such as DOT. Additionally, given the known relationship between a PA image and local
optical absorption, it is possible to rewrite the model equations such that an unknown parameter (i.e., absorber concentration) equals a known function of itself, leading to fixed-point [74]
or model-based [51] iteration approaches. In this work, a surface-fluence correction method
is developed (chapter 5), which allows for a "semi-quantitative" analysis without requiring significant computing resources for the correction, as is required for some of the aforementioned
iterative strategies.

2.3.3 Multispectral Optoacoustic Tomography (MSOT)
Multispectral optoacoustic tomography (MSOT) is a specific implementation of multi-wavelength
PA imaging whereby the laser illumination and subsequent acoustic detection are implemented
in a tomographic geometry (rather than with a conventional linear US array), allowing for increased sensitivity with US-scale spatial resolution in whole-body preclinical imaging (Figure 2.5) [75, 76]. Due to the non-ionizing radiation used for imaging, it is a relatively safe
imaging modality and allows for repeated longitudinal imaging in the same subject [76]. How13

ever, it can be challenging to co-register subsequent time-points due to discrepancies in the
mouse setup on different days. Additionally, because a B-mode US image is commonly not
acquired with MSOT data, there is no matched anatomical data to reference with the PA data.
Co-registration to other anatomical imaging modalities, such as CT, has been investigated, but
again, such registration is difficult due to differences in the configuration of the subject across
different modalities [77, 78]. This work explores these co-registration challenges with both
x-ray CT in chapter 3 and with MRI in chapter 5.

Mouse Holder

MSOT inVision Array

Plastic Foil

Laser Fiber Bundles
Nose Cone
Figure 2.5: MSOT Imaging. In the multispectral optoacoustic tomography (MSOT) inVision
preclinical PA imaging system (iThera Medical, Munich, DE), mice are imaged with tomographic laser illumination and acoustic detection, allowing for increased sensitivity. The mouse
holder design allows for whole-body imaging with repeated imaging in the same subject over
multiple time-points. The mouse is placed into the holder, and oxygen and isoflurane anesthesia are supplied via the nose cone. The plastic foil is wrapped around the holder, then the
holder is submerged in a water bath for imaging.
In MSOT post-processing, the tomographic backprojection reconstruction algorithm often
suffers from artifacts due to heterogeneous biological tissue [79]. In large part, this is due to
minimal corrections made on the optical side of the MSOT reconstruction problem: because
the light is attenuated differently for different wavelengths, fluence corrections, as discussed in
subsection 2.3.2, are necessary to achieve quantitative MSOT imaging [79]. In part, this work
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will discuss some fluence correction strategies that have been implemented to try to move
towards more quantitative PA imaging on the MSOT platform.
Additionally, the MSOT geometry has been applied to the clinical MSOT Acuity PA-US
imaging system (iThera Medical, Munich, DE). To achieve the tomographic imaging geometry,
the elements on a 2D handheld probe are arranged along an arc on a 40mm radius spherical
surface [80]. This system has received European CE marking [81] and has shown promise for
imaging applications such as breast cancer and vascular disease [82].

2.3.4 Clinical PA Imaging
Despite recent advances, clinical PA imaging is facing formidable challenges. For clinical success, PA imaging systems must deliver accurate quantitative imaging with sufficient spatial
resolution to appropriately assess heterogeneity in a given region of interest (ROI). With multiwavelength PA imaging, endogenous and exogenous absorbers can be identified voxel-wise
through the imaging volume via linear spectral unmixing [51] or more complex inversion techniques [63]. In a heterogeneous in vivo environment, however, local fluence variation introduces complex spectral coloring and affects PA-based estimates of chromophore distributions,
making robust PA imaging at depths greater than 2 cm a challenge [83]. Such (unknown) fluence variations already make accurate spectral unmixing difficult [84], so the introduction of
an exogenous agent with identifying spectral features that overlap with those of hemoglobin
further confounds these methods. To mitigate this effect, it is critical that absorption spectra
of exogenous agents maintain minimal overlap with the most relevant and dynamic regions
of endogenous contrast. Ideally, clinically translatable PA contrast agents should provide high
contrast at depth after spectral unmixing from background hemoglobin, maintain molecular
specificity to cellular targets, afford sufficient stability during imaging, and have a composition
amenable to translation (i.e., biocompatible and scalable for clinical production) [85–87].
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2.4 PA Contrast Agents
2.4.1 Endogenous Contrast Agents
One of the key advantages of PA imaging is the inherent contrast from endogenous chromophores, such as hemoglobin, lipids, and melanin [12]. Endogenous agents allow for molecular imaging without the need to introduce an exogenous agent, which can perturb the system
and cause unwanted changes that obscure the physiology under investigation [88]. Additionally, endogenous PA agents have been shown to be independent biomarkers in specific applications [16, 89]. As introduced in subsection 2.2.1, the most promising of these biomarkers is
SO2 , which provides information about the blood oxygenation status via PA-based estimation
of HbO2 and HHb. Because it does not require an exogenous agent, PA imaging for SO2 estimation is being investigated in clinical trials, particularly in applications that show significant
changes in vasculature (e.g., cancer and inflammation) [90]. In chapter 4, SO2 is explored as
a biomarker to observe disease progression in acute lymphoblastic leukemia (ALL). However,
endogenous contrast is not sufficient for noninvasive visualization of other physiological processes, such as cell receptor expression; for these applications, it will be necessary to employ
exogenous agents.

2.4.2 Exogenous Contrast Agents
A number of inorganic exogenous contrast agents have been investigated for PA imaging.
AuNPs gained early popularity as PA contrast agents due to their high absorbance coefficient
[91], readily tunable optical properties by varying their size and shape, and silica coating modification that allows for increased in vivo stability and PA signal generation [92, 93]. Silver
nanoparticles and nanoplates have also been explored, but in vivo stability and toxicity concerns limit their preclinical utility and potential for clinical translation [94]. Ultimately, while
many of these agents have demonstrated impressive phantom and preclinical imaging results,
they tend to be composed of materials that lack FDA approval, making the barrier to clinical
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translation relatively high.
Alternatively, organic dyes are commonly used as PA contrast agents as they are widely
commercially available [86]. However, many such dyes and dye-conjugates are not particularly well suited for PA imaging, with a molar extinction coefficient that can be 4 to 6 orders of
magnitude less than gold-based contrast agents [87], making imaging at depth a serious challenge. Further, most common dyes have absorbance peaks in the 600-800 nm region, which
interferes with SO2 quantitation [59]. Theranostic porphysomes have been shown to produce a
strong PA signal [95, 96] by a tight packing of porphyrins inside liposomal membranes; yet porphyrins are well-known photosensitizers, and thus these agents can interfere with monitoring
of therapeutic interventions [97]. Recently, aggregates formed by non-biologically-active chromophores, such as naphthalocyanines [98], aza-BODIPY [99], and dicarboxyphenyl cyanine
[100], were introduced for sensitive PA imaging. However, these reports did not demonstrate
the ability for quantitative, targeted molecular PA imaging in vivo, and the chromophores used
in these studies are not FDA-approved, which could significantly delay clinical translation.

2.4.2.1 ICG
One particular dye that has gained significant attention for PA imaging due to its FDA approval status (i.e., for determining hepatic blood flow and for ophthalmic angiography [101])
is indocyanine green (ICG). However, while ICG generates a reasonably strong PA signal, its
absorption peak is near the ideal wavelengths for hemoglobin unmixing, making it difficult to
spectrally differentiate in vivo and drastically reducing its PA imaging sensitivity. Moreover, the
short half-life of ICG in circulation [102] limits its use in disease monitoring or for systemic
delivery. Other groups that have explored ICG encapsulation and/or lipid-ICG complexes have
used the monomeric form of ICG [103]. The downside of this form is low molar extinction coefficients (in the range of 2.7×105 cm-1 /M for ICG), which can be hard to detect at depth in
tissue with PA imaging.
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2.4.2.2 Lipo-JICG
Here we introduce a novel nanoparticle with a combination of properties that have promising
potential to address all clinical needs for a PA contrast agent. Our agent’s design embodies
the following basic concepts: (i) dye aggregates, which exhibit a strong PA signal and high
photostability; (ii) liposomal encapsulation, enabling stability, prolonged circulation time, and
efficient delivery of its cargo; (iii) separation of distinct spectral features of hemoglobin and
the agent, allowing accurate and simultaneous SO2 estimation and contrast agent quantitation
(Figure 2.7); and (iv) molecular targeting in vivo, enabled by directional conjugation [9, 104] of
contrast agents with monoclonal antibodies. Further, our agent can be sourced from entirely
FDA-approved components, thus reducing the barrier to clinical translation relative to other
available agents. Taken together, these features – which have not been previously achieved in
a single PA contrast agent – can facilitate simultaneous, quantitative, molecular, and functional
PA imaging in clinical applications.
To achieve the aforementioned combination of properties, we developed and validated a
PA contrast agent, Lipo-JICG (Figure 2.7a), that is based on liposomal encapsulation of ICG
at a high enough concentration for formation of stable J-aggregates [105]. This configuration results in drastically improved PA signal generation due to increased thermal gradients
(from tightly clustered absorbers [93]) and a narrow absorption peak at 890 nm, which provides increased optical absorption and allows for robust detection sensitivity in the presence
of hemoglobin (Figure 2.6). As shown in Figure 2.7b, Lipo-JICG presents with a sharp spectral feature in the 870-920 nm range, where the spectra from hemoglobin remain relatively
flat. Conversely, Lipo-JICG’s relatively flat absorption spectrum from 760-830 nm facilitates
accurate PA-based SO2 estimation [12], which is critical for better understanding the dynamics associated with tumor microenvironment regularization [106]. Unmixing monomeric ICG
from hemoglobin, on the other hand, requires multi-wavelength unmixing of both absorbers in
the same wavelength range, confounding PA quantification at varying SO2 percentages and
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Figure 2.6: Spectral comparison of photoabsorbers. Lipo-JICG (dark green trace)
presents with sharp spectral features (lime region from 870-920 nm) where the spectra from
hemoglobin (red, blue traces) remain relatively flat. This provides Lipo-JICG with robust detection sensitivity to sample its ∼890nm peak. Further, its relatively flat spectrum from 760830 nm facilitates accurate quantification of PA-based SO2 estimates, which is critical for
understanding dynamics associated with tumor microenvironment regularization. Unmixing
monomeric ICG (gold/olive traces; spectra provided in blood serum) from hemoglobin, on the
other hand, requires multi-wavelength imaging in a (light yellow) region that overlaps with
distinct spectral features from hemoglobin, confounding PA quantification at varying SO2 percentages and ICG concentrations.
ICG concentrations. Additionally, liposomal formulation of Lipo-JICG allows for PEGylation
and conjugation with targeting moieties, improving biocompatibility and conferring specificity
against targeting sites, respectively. Molecular targeting of Lipo-JICG is enabled with directional conjugation [104], whereby antibodies are conjugated through the Fc portion, leaving
antigen-binding sites on the Fab moiety available for targeting. This diminishes potential nonspecific interactions through Fc receptors that are present on some cells. All of these characteristics allow Lipo-JICG to be a robust agent that makes quantitative, molecular PA imaging
in both preclinical and clinical usage more feasible.
In chapter 3, the synthesis, bioconjugation, and characterization of liposome-encapsulated
ICG J-aggregates (i.e., Lipo-JICG; Figure 2.7) for molecular PA imaging is described. Additional Lipo-JICG validation is shown in chapter 3 and chapter 5 in phantom, in vitro, and in
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vivo PA imaging environments for both spectral unmixing accuracy and targeting efficacy with
a folate receptor alpha-positive (FRα+) ovarian cancer model.
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Figure 2.7: Lipo-JICG design. (a) Schematic of FRα-targeted Lipo-JICG nanoparticle (FRαLipo-JICG). (b) Optical absorbance spectra of endogenous HbO2 (red) and HHb (blue) with
exogenous monomeric ICG in blood serum (gold) and Lipo-JICG (green) demonstrate advantages of unmixing PA images for Lipo-JICG in the presence of blood. Notably, Lipo-JICG’s
sharp 890nm peak facilitates greater spectral separation from hemoglobin, while increased
peak optical absorption relative to concentration-matched ICG increases PA signal generation.
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Chapter 3: Characterization of Multi-Wavelength PA Imaging
Methods
3.1 Introduction
PA imaging is a functional and molecular imaging technique capable of high sensitivity and
spatiotemporal resolution at depth. With multi-wavelength PA imaging, PA-based estimates
of endogenous (i.e., hemoglobin) and exogenous chromophores can provide a map of imaging biomarkers, which can guide improved diagnosis and patient-specific treatment strategies.
However, accurate quantification of multi-wavelength in vivo PA imaging data is challenging
due to local fluence variations that arise from the inherent heterogeneities in biological tissue.
Adding an exogenous agent to this in vivo environment further confounds these PA estimations, particularly because currently available contrast agents either lack PA-signal-generation
ability for deep imaging or their absorbance spectra overlap with hemoglobin, reducing imaging sensitivity. We address these limitations with a novel PA contrast agent based on targeted
liposomes loaded with J-aggregated indocyanine green dye (i.e., Lipo-JICG). As shown in
this chapter, this agent exhibits highly advantageous properties for in vivo PA imaging: (i) a
strong, narrow absorbance at ∼890 nm, allowing for straightforward unmixing from endogenous hemoglobin; (ii) PA signal enhancement from dye-aggregation-mediated increases in
thermal gradients and absorbance; (iii) a concentration-independent spectrum, allowing for
quantitative PA imaging with simple post-processing; and (iv) molecular specificity in an in
vitro setting. Additionally, Lipo-JICG’s composition of FDA-approved components makes it a
promising agent for future clinical molecular PA imaging.
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3.2 Methods
3.2.1 Composition and synthesis of Lipo-JICG
Lipo-JICG was formed by a combination of lipid film hydration, sonication, and membrane extrusion methods. A combination of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPEmPEG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)2000] (DSPE-PEG-Mal), and cholesterol (Avanti Polar Lipids, Alabaster, AL) was added to a
100mL, round-bottom flask at a molar ratio of 90:7.5:1:1.5, respectively. One hundred mL of
chloroform was used to solubilize the 100mg lipid mixture, then a lipid film was produced inside the flask by rotary evaporation at 40◦ C. Once the film was produced, a 100mL solution of
United States Pharmacopeia (USP) Reference Standard grade ICG (MilliporeSigma, Burlington, MA) at a concentration of 1.0 mg/mL in a 10mM 2-(N-morpholino)ethanesulfonic acid
(MES) buffer, pH 5.0 was added to the flask. After hydration of the lipids, the solution was sonicated using a probe sonicator equipped with a microtip (Branson Ultrasonics Corp., Danbury,
CT) at the lowest power setting and a 10% duty cycle for 60 min. During sonication, the flask
was partially submerged in a temperature-controlled water bath set to 40◦ C. Then, sodium
azide was added at a concentration of 0.01% to inhibit potential bacterial growth. The solution
was capped and stored in the dark until the absorbance at 890 nm was >3x the absorbance at
780 nm, which was approximately 60 days.
Once the ICG J-aggregates formed, the solution was passed through a 0.45µm PVDF filter, followed by a 0.22µm PVDF filter (MilliporeSigma). The 100mL solution was then dialyzed
using 300kDa dialysis tubing (Spectrum Labs, San Francisco, CA) against 10 L of 10mM MES
buffer, pH 6.0, for 5 days at 4◦ C. This step was repeated a minimum of 3 times, and the liquid
which permeated through the centrifugal filter was measured by a Cary 60 UV-Vis-NIR spectrophotometer (Agilent Technologies, Inc., Santa Clara, CA) to confirm removal of free ICG.
The final Lipo-JICG suspension was then concentrated using a 100,000 MWCO centrifuge
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filter (MilliporeSigma) in a swinging bucket centrifuge (Eppendorf, Enfield, CT) operating at
1,500 g. The concentrated PAtrace solutions were then passed through a 0.45µm PVDF filter, followed by a 0.22µm PVDF filter. Finally, the solutions were extruded 12 times through
a 100nm-pore-size polycarbonate membrane (Avanti Polar Lipids) using an extruder (Avanti
Polar Lipids) with two 1mL glass syringes. The Mal-Lipo-JICG was stored at 500 OD at 4◦ C
until use.
To determine the number of ICG molecules per Lipo-JICG nanoparticle, the number concentration of Lipo-JICG was measured by tunable resistive pulse sensing [107, 108] using a
qNano Gold system (Izon Science Ltd., Oxford, UK). A Lipo-JICG suspension was first filtered
through a 0.45µm PVDF syringe filter (CELLTREAT, Pepperell, MA) and diluted ∼100 times in
the injection buffer (Dulbecco’s PBS with wetting solution concentrate; Izon Science Ltd.) to be
∼5 OD, then added to the qNano Gold system equipped with an NP150 nanopore membrane.
The concentration of nanoparticles was determined based on their flow rate through the membrane under 5 mbar of pressure. To measure the concentration of ICG dye molecules, the
Lipo-JICG sample was mixed with ethanol to achieve a 1:1 v/v ethanol/water ratio. Under this
condition, the liposomal coating is dissolved, and ICG J-aggregates dissociate to monomeric
ICG molecules almost instantly. Then, the absorbance of the ICG solution at 790 nm was
measured using a Synergy HT Microplate Reader (BioTek Instruments, Winooski, VT), and
the concentration of ICG molecules was determined using a linear calibration curve of ICG
(R2 =0.999) in 1:1 v/v ethanol/water solution.

3.2.2 Directional bioconjugation of Lipo-JICG
Anti-FRα monoclonal antibodies (Thermo Fisher Scientific, Waltham, MA) were directionally
conjugated to Lipo-JICG containing maleimide reactive thiol groups using a heterobifunctional
linker [104]. The linker consists of a polyethylene glycol (PEG) chain terminated at one end
by a hydrazide moiety and at the other end with a thiol group - hydrazide-PEG-thiol linker
(PG2-HZTH-3k; Nanocs, New York, NY). The glycosylated Fc region of the antibodies was first
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mildly oxidized to form aldehyde groups at the terminal carbohydrate moieties. Antibodies were
reconstituted at 2 mg/mL in 100mM sodium phosphate buffer, pH 7.5. In a typical reaction,
a 100 µL aliquot of 100mM sodium periodate was added to the 500µL antibody solution to
achieve ∼1,700 molar excess for 30 min. The oxidation reaction was quenched by addition
of PBS at 10-fold excess v/v. Then, 20 µL of hydrazide-PEG-thiol linker, stored at 46.5 mM
in EtOH solution (EtOH:H2 O 1:1 v/v), was added to 6 mL of the oxidized antibody solution
(∼170 molar linker excess) for 30 min. Unreacted linker was removed by two purification steps
using a 10,000 MWCO centrifugal filter (MilliporeSigma) at 3,100 g for 20 min. The purified
thiol-modified antibodies were reconstituted in 40mM HEPES (pH 8.4) at 1 mg/mL and then
were mixed with Mal-Lipo-JICG suspension at 500 OD in 10mM MES buffer, pH 6.5, at 10:4
volume ratio. The pH value was adjusted to pH 8, and the conjugation reaction was allowed to
proceed for 1 hr at room temperature. During the conjugation step, a stable thioether linkage
bond is formed between Lipo-JICG and antibodies. Unreacted free antibodies were removed
by aspiring supernatants after centrifugation of the mixture at 17,200 g for 30 min twice. The
resulting conjugates were stored in sterilized PBS at 100 OD and 4◦ C.

3.2.3 Transmission electron microscopy of Lipo-JICG
Lipo-JICG (10 µL, 10 OD) was placed on 100-mesh copper grids coated with carbon and formvar and pretreated with poly-l-lysine for ∼1 hr, then negatively stained with Millipore-filtered
aqueous 2% uranyl acetate. The stain was blotted dry from the grids with filter paper, and
the samples were allowed to dry. Samples were then examined on a JEM-1010 transmission electron microscope (JEOL USA, Inc., Peabody, MA) at an accelerating voltage of 80
kV. Digital images were obtained using the AMT Advantage HR/HR-B CCD Camera System
(Advanced Microscopy Techniques, Corp., Danvers, MA). The size distribution of Lipo-JICG
was assessed on TEM images using ImageJ 3.0 software, which provides a digital caliper
tool [109]. First, the scale was set according to the TEM image scale bar. Then, the diameter of each Lipo-JICG nanoparticle in the TEM images was measured using digital calipers.
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Fifty-four Lipo-JICG nanoparticles from five independently acquired TEM images were used to
determine the Lipo-JICG size distribution.

3.2.4 Spectral comparison of Lipo-JICG to monomeric ICG
Lipo-JICG was centrifuged at 50 g for 10 min to remove any potential aggregates. After centrifugation, the supernatant was collected and measured with UV-Vis-NIR spectrophotometry;
Lipo-JICG was diluted to 2 OD at 890 nm with PBS buffer for the UV-Vis-NIR measurement.
Then, ICG was released from Lipo-JICG by mixing 200 µL of 5% Tween 20 (MilliporeSigma) in
PBS with 200 µL of the 2 OD stock Lipo-JICG; this spectrum was compared with 200 µL of 2
OD stock Lipo-JICG mixed with 200 µL PBS. After mixing for 30 min, absorbance spectra were
acquired in a Synergy HT Microplate Reader (300-950 nm; 2nm step size). All measurements
were carried out in triplicate. Note that all UV-Vis-NIR absorbance spectra were measured
with a path length of 1 cm.

3.2.5 Stability of Lipo-JICG in different media
The stability of the Lipo-JICG absorbance spectrum was tested for varying temperatures (4◦ C
& 37◦ C) and solutions (PBS, 10% FBS in DMEM, & 100% FBS) at multiple time-points (6 hr,
24 hr, 48 hr, 1 week, & 1 month). Triplicate samples were incubated for each condition at 2 OD.
Absorbance spectra were collected in the Synergy HT Microplate Reader (400-950 nm; 2nm
step size). Triplicate absorbance values were averaged, and spectra were plotted for each
condition.

3.2.6 Fluence stability measurements
Samples were injected into a glass tube and submerged in water to facilitate coupling with
the US transducer. PA images and spectra were acquired with the Vevo 2100 LAZR highfrequency PA-US imaging system (FUJIFILM VisualSonics, Toronto, Canada) using a linear
array transducer (LZ250; 21MHz center frequency) with a 2.4cm field of view and a nominal
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5Hz frame rate. Images were acquired to determine the spectral peak of each agent (680-970
nm; 37dB gain; persistence of 8). Each sample was then exposed to 900 laser pulses at its
respective maximum-PA-signal wavelength for seven different fluence conditions (1, 2, 5, 10,
15, 20, & 25 mJ/cm2 ). To determine the stability of the nanoparticles, the PA signal at each
fluence from all pulses was averaged and plotted versus fluence.

3.2.7 Photothermal stability measurements
To assess photothermal stability of FRα-Lipo-JICG and monomeric ICG, 20 µL of either FRαLipo-JICG or ICG in 50% EtOH was injected into a 0.4mm-inner-diameter polyethylene tube
(Becton, Dickinson and Company, Franklin Lakes, NJ). Each tube was then imaged with the
Vevo 2100 LAZR system (680, 730, 760, 780, 790, 810, 830, 850, 870, 880, 890, 900, 920,
940, & 970 nm; 40dB gain; persistence of 6). The spectral scan was repeated four times,
which exposed the sample to 1,440 pulses over the PA spectral acquisition. An ROI was
manually placed in the center of the tube, and the PA signal was averaged within the ROI.
The imaging and analysis procedure was repeated across four tubes. For each tube, the four
spectra were normalized by the mean of the first spectrum’s PA values. The mean (±SD)
was then calculated across the four tubes’ normalized spectra, and the first and last spectra
were plotted versus wavelength for comparison, while agreement between these spectra was
assessed with a correlation coefficient.

3.2.8 Studies in multi-well gelatin phantoms
To assess linearity of PA signal generation, Lipo-JICG (or ICG) was placed in a gelatin phantom with multiple sample wells (Figure 3.1), as described previously [110, 111]. Briefly, a
polydimethylsiloxane (Dow Corning, Midland, MI) 3D-printed mold was used to create 36 semiellipsoidal inclusions, each with a volume of ∼57 µL. The phantom background was comprised
of 8% w/v 225-Bloom, Type B gelatin, 1% v/v propanol and 0.1% v/v glutaraldehyde (MilliporeSigma). Lipo-JICG (or ICG in 4% (w/v) bovine serum albumin in water) was serially diluted
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from 25 to 1.6 OD, then each concentration was mixed with a 16% w/v gelatin solution in a
1:1 v/v ratio before decanting into inclusions in the phantom. All samples were prepared in
triplicate. A final ∼3mm layer of gelatin was deposited atop the inclusions to immobilize the
cells in each well. Volumetric B-mode US and multi-wavelength PA images were acquired with
the Vevo 2100 LAZR system (710, 730, 780, 830, 870, 890, 900, 910, & 920 nm; 0.47mm step
size; 40dB gain; persistence of 6). Average PA signal in each inclusion was obtained through
volumetric segmentation of B-mode US images at the same dynamic range. Laser fluence
ranged from 0.3 to 0.9 mJ/cm2 in the analyzed region at the center of the sample.

CAD Mold Design

PA-US
Transducer

Sample Well Negatives
Gelatin
Phantom

3D Printed Mold

Gelatin
Block
Gelatin Background
Sample Well

Figure 3.1: Multi-well gelatin phantom. A multi-well phantom mold was designed in CAD
software (upper left) and 3D printed (lower left). The mold was used to create a gelatin phantom with 36 semi-ellipsoidal wells (lower left), and samples were decanted into each well. The
phantom was adhered atop a gelatin block before imaging with the Vevo 2100 LAZR system
(right).
The same phantom was used for in vitro PA cell imaging studies. SKOV3 (FRα+) and
A2780 (FRα-) cells were seeded at 1×106 cells/well in a 6-well cell-culture plate and incubated
overnight. Lipo-JICG, conjugated with either non-targeted anti-RG-16 (MilliporeSigma) or targeted anti-FRα antibodies, was then added at 3.5 OD per well and incubated for 2 hr at 37◦ C.
Unbound particles were removed by washing with PBS; cells were removed by trypsinization
and collected by centrifugation at 300 g for 10 min. Resulting cell pellets were reconstituted in
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∼100 µL of 4% v/v paraformaldehyde solution (Electron Microscopy Sciences, Hatfield, PA) in
PBS. Reconstituted cells were then mixed with 16% w/v gelatin in a 1:1 v/v ratio before transferring to gelatin phantom wells. A final ∼3mm layer of gelatin was deposited over the top of
the inclusions. The phantom was then imaged with the Vevo 2100 LAZR system, as described
previously. All samples were prepared in triplicate.

3.2.9 Tissue-mimicking phantom comparison of Lipo-JICG to monomeric ICG
Experiments were conducted in tissue-mimicking phantoms to demonstrate advantages of
Lipo-JICG over monomeric ICG in accurate quantification of PA imaging data with SNR that
would begin to emulate the in vivo condition at depth. To this end, a 0.4mm-inner-diameter
polyethylene tube was embedded in a 2cm diameter 8% m/m 225-Bloom, Type B gelatin cylinder with 0.6% m/m silica, 0.01% m/m India ink, and 8% m/m Intralipid added, which was based
on previous work [110]. Heparinized porcine blood (Animal Technologies, Tyler, TX) was prepared at specific SO2 percentages, as described previously [59], and mixed with PBS at a 9:1
ratio to approximate a 10% v/v of blood. Mixtures of Lipo-JICG (or ICG) with blood were then
prepared to achieve 0.3/0.9 probe OD and 50%/70% blood SO2 , injected into the tube, and
imaged in the inVision system (710, 734, 760, 800, 830, 870, 890, 900, & 920 nm; 10-frame
averaging). Blood-only samples were also imaged as controls for SO2 unmixing. The spectral data from each acquisition was plotted and compared to its theoretical spectrum, which
was calculated as the superposition of optical absorption spectra of 0.3/0.9 probe OD and
50%/70% blood SO2 ; agreement between experimental and theoretical spectra was assessed
with a correlation coefficient. Note that 1.7 µM Lipo-JICG (i.e., ICG dye concentration in LipoJICG formulation) and 5.1 µM ICG (i.e., triple the concentration) are both equal to 0.9 OD when
measured at their respective spectral peaks.
PA images were linearly unmixed in MATLAB for HbO2 , HHb, and Lipo-JICG (or ICG). The
following wavelengths were used: 710, 734, 760, 800, 830, and 870 nm. The voxel with the
maximum 800nm PA signal was automatically selected on each axial image, a 3x3 ROI was
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centered on that voxel, and the SO2 estimate and Lipo-JICG (or ICG) signal within all ROIs
were assessed across all z-slices (see “PA post-processing and ROI selection” section). To
validate the temporal stability of blood samples in the sealed PE tubes, two samples (i.e.,
50% & 75% SO2 ) were tested by injecting the sample into the tube, then monitoring with
a repeated, multi-wavelength PA imaging sequence for 5 min to ensure that SO2 temporal
stability was achieved through the duration of the phantom experiments (described below). In
both samples, the SO2 estimates did not change by more than 5%.
The wavelength combination used for unmixing was determined by a cost function, which
included: mean SO2 error between PA-based SO2 estimates without and with probe; error
in the Lipo-JICG (or ICG) signal ratio from a 3-fold increase in concentration; and number of
wavelengths (Figure 3.2). The phantom-experiment cost function relies on the fact that we
obtain PA-based SO2 estimates of blood samples without exogenous probe (i.e., either LipoJICG or ICG) and that we also obtain PA-based probe estimates of blood samples mixed with
known probe-concentration increases (i.e., from 0.3 to 0.9 OD). The cost function optimizes
for both the accuracy of probe unmixing (i.e., error between known and PA-based estimates
of increases in probe concentration) and SO2 estimation (i.e., error between PA-based SO2
estimates for a blood sample with and without probe present), while it requires that the same
wavelengths be used for both Lipo-JICG and ICG acquisitions to help ensure a fair comparison.
To promote faster acquisition times, a modest penalty (i.e., square root) was included for the
number of unmixing wavelengths used.

3.3 Results
3.3.1 Characterization of Lipo-JICG
The size distribution, spectrum, loading efficiency, stability in various media, fluence stability,
and PA-signal-concentration linearity were evaluated to characterize Lipo-JICG. The size distribution, which was assessed via transmission electron microscopy (TEM), showed a mean
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Figure 3.2: Cost function for phantom wavelength selection. Optimized wavelengths for
unmixing of hemoglobin and Lipo-JICG (or ICG) were determined by a cost function (first
equation, bottom; bar plot, left), which included: mean absolute SO2 estimation error, which
is the average difference between SO2 estimates with and without probe, within the PE-tube
ROI (second equation, bottom; this error was calculated and summed for the 50% & 70% SO2
samples [i.e., nSO2 = 2] mixed with 0.9 OD probe); absolute error in the probe signal ratio
relative to the expected ratio of 3, where Probe signal is Lipo-JICG (or ICG) signal within the
ROI at the concentration denoted by the subscript (last equation, bottom); and the number
of wavelengths (nWL), which accounts for the overall scan time. SO2 and Probe error are
weighted more heavily than the number of wavelengths, and the cumulative cost function is
the summation of the individual ICG and Lipo-JICG cost-function calculations to choose an
optimized wavelength combination for both probes. The wavelength combination obtained
from the minimum of the cost function is indicated by a red asterisk (bar graph, top left).
Eleven wavelength combinations were tested (table, right).
(±standard deviation [SD]) particle size of 130 (±37) nm (Figure 3.3; Figure 3.4a-b).
Spectral characterization was performed on both intact Lipo-JICG (i.e., J-aggregated form)
and ICG released from Lipo-JICG (i.e., monomeric form) with UV-Vis-NIR spectrophotometry;
for this comparison, Lipo-JICG was mixed with Tween 20 at 5% concentration to disrupt the
liposomal coating and to dissociate ICG J-aggregates into monomeric ICG molecules. Compared to monomeric ICG, the Lipo-JICG absorbance peak is increased by ∼3 fold, narrowed
to 30% of the full width at half maximum of ICG, and red-shifted by ∼100 nm from the 800nm
monomer peak to the ∼890nm peak of ICG J-aggregates, as shown in Figure 3.4c. Note that
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Figure 3.3: TEM images. Sample TEM images of Lipo-JICG nanoparticles with different
magnifications. Black scale bar to the bottom-right of each image indicates 100 nm.
the absorbance peak varies from 880-890 nm between production batches of Lipo-JICG. We
also quantified the loading efficiency of Lipo-JICG as the number of ICG dye molecules per
nanoparticle. Our data show that Lipo-JICG solution at 1 Optical Density (OD) has ∼8.88×108
Lipo-JICG nanoparticles/mL and ∼1.37×1015 ICG molecules/mL. Therefore, each Lipo-JICG
nanoparticle contains ∼1.54×106 ICG molecules. This loading efficiency of ICG dyes per
liposomal nanoparticle is ∼4×102 greater than what is reported for liposomes loaded with
monomeric ICG dyes [103]. This significant increase in the loading efficiency of Lipo-JICG is
most likely associated with a dense packing of ICG J-aggregates.
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Figure 3.4: PAtrace characterization. (a) Representative image of Lipo-JICG TEM (scale bar
100 nm), which measured (b) a size distribution of 130 (±37) nm across all TEM images (N=5).
(c) Spectral characterization of intact Lipo-JICG (green) and ICG released from Lipo-JICG by
addition of 5% Tween 20 in water (gold) demonstrates that at equimolar concentrations, LipoJICG yields an absorbance spectrum that is red-shifted, narrower, and of increased peak
absorbance compared to monomeric ICG.
Temporal stability was tested via assessment of the UV-Vis-NIR absorbance spectrum for
varying temperatures and solutions at multiple time-points (Figure 3.5). At the storage condition of 4◦ C in PBS, Lipo-JICG did not show significant spectral changes through one month,
indicating a long shelf life. At 37◦ C in 10% FBS, no significant spectral changes were observed
over 48 hr; however, in 100% FBS at 37◦ C, the 890nm-to-790nm ratio reduced by 22% after 6
hr, 41% after 24 hr, and 50% after 48 hr, indicating that Lipo-JICG particles degrade progressively and de-aggregate into monomeric ICG in the presence of serum and at physiological
temperature. Our in vivo studies (see “Molecular PA imaging of an ovarian cancer model”
section) indicate that this stability is sufficient for molecular PA imaging in ovarian cancer models, which require an approximately 30-60 min imaging window. Further, biodegradation of
Lipo-JICG could be leveraged for longitudinal measurements with repeated injections of the
agent.
Fluence stability was assessed by exposing contrast agents to varying laser-pulse energies
during PA imaging. We compared fluence stability of Lipo-JICG, monomeric ICG, silica-coated
(SiO2 ) AuNRs (which are considered the best commercially available contrast agent for PA
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Figure 3.5: Temporal stability of Lipo-JICG in different media. Assessment of Lipo-JICG
at (a,d) 4◦ C in PBS demonstrates minimal spectral changes over one month, indicating a
long shelf life. At (b,e) 37◦ C in 10% FBS, no significant changes were observed; however, at
(c,f) 37◦ C in 100% FBS, the 890nm-to-790nm ratio reduced by ∼50% after 48 hr. Error bars
indicate SD across three absorbance acquisitions.
imaging [92, 112]), and water (Figure 3.6). Each sample was excited at its corresponding
maximum absorption wavelength. The average PA signal from 900 laser pulses at each fluence
was then normalized by the absorber mass to provide a metric for fluence stability. Nonlinearity
in the PA signal with increasing fluence indicates that irreversible changes to the agent were
occurring. Lipo-JICG exhibited high fluence stability, presenting a linear PA signal up to ∼15
mJ/cm2 . Conversely, SiO2 AuNRs started to become nonlinear at >2 mJ/cm2 . Lipo-JICG also
exhibited a 5-fold increase in PA signal over free ICG when both had the same dye molarity.
Finally, to test the concentration linearity of PA signal generation, multi-wavelength PA
imaging was conducted on Lipo-JICG (or ICG) embedded in a gelatin phantom (Figure 3.1)
at concentrations ranging from 25 to 1.6 OD. PA spectra of Lipo-JICG remained constant at
varied OD (Figure 3.7a-b), while PA signal at the spectral peak (i.e., 880 nm) remained linear
with increasing OD (Figure 3.7c). In contrast, PA spectra of ICG were only constant up to 12.5
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Figure 3.6: Fluence stability of imaging contrast. (a) PA imaging at each absorber’s peak
wavelength with increasing laser fluence of Lipo-JICG (green) demonstrates high fluence stability, presenting a near-linear mass-normalized PA signal up to 15 mJ/cm2 . Conversely, SiO2
AuNRs (maroon) become nonlinear at >2 mJ/cm2 . (b) Corresponding optical absorbance
spectra indicate a matched peak OD that was used for all particles tested. The concentration of the absorbers, with the exception of water, were controlled so that the absorbance at
the peak wavelength was 5 OD.
OD (Figure 3.7d-e), and PA signal at the spectral peak (i.e., 810 nm) was linear up to 12.5 OD
(Figure 3.7f) as a significant spectral shift was observed at 25 OD due to aggregation of ICG
molecules (Figure 3.7d). Note that the absorption peak of monomeric ICG shifts from 790 nm
to 810 nm when it binds to albumin, which is present in blood serum [113].
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Figure 3.7: PA imaging of serial dilutions of Lipo-JICG and ICG. (a) PA imaging of serial
dilutions (25-1.6 OD; fluence 0.3-0.9 mJ/cm2 ) of Lipo-JICG exhibits a constant spectrum over
varying concentrations, while (b) normalization of these PA spectra shows spectral stability
(error bars removed for visibility). (c) Peak PA signal remains linear with increasing OD, up
to 25 OD. (d) PA imaging of serial dilutions (25-1.6 OD) of monomeric ICG dissolved in 4%
bovine serum albumin in water. (e) As shown by normalized spectra, PA signal from ICG is
stable up to 12.5 OD. Note that because no substantial ICG PA spectrum was observed at 1.6
OD, its normalized PA spectrum at this concentration amplifies the noise. (f) Peak PA signal
for ICG remains linear up to 12.5 OD.

3.3.2 Comparison of Lipo-JICG with ICG in a phantom environment
To demonstrate advantages of Lipo-JICG over monomeric ICG for PA signal generation and
spectral unmixing in the presence of blood, a polyethylene tube was embedded in a cylindrical tissue-mimicking phantom (Figure 3.8a), and mixtures of Lipo-JICG (or monomeric ICG)
and porcine blood were injected into the tube and imaged in the preclinical MSOT inVision
256-TF PA imaging system (iThera Medical, Munich, DE) over multiple wavelengths. Images
were linearly unmixed for hemoglobin (i.e., to assess SO2 ) and Lipo-JICG (or ICG). Example
800nm PA images of the phantom are shown in Figure 3.8b, with insets showing SO2 and
Lipo-JICG (or ICG) images of the tube ROI for 0.9 OD Lipo-JICG (or ICG) with co-mixed 70%
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SO2 blood. Note that for all PA imaging experiments, “SO2 image” and “Lipo-JICG (or ICG)
image” are defined as image matrices that provide measurements of SO2 percentage and
relative Lipo-JICG (or ICG) concentration, respectively, based on multi-wavelength unmixing;
“SO2 estimate” and “Lipo-JICG (or ICG) signal” are scalars obtained by taking the spatial average of their respective matrices over a given ROI (see “PA post-processing and ROI selection”
section).
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Figure 3.8: Phantom comparison of Lipo-JICG and ICG in blood-containing phantom.
(a) Schematic of tissue-mimicking (TM) phantom for multi-wavelength PA imaging with an embedded polyethylene (PE) tube for assessment of combinations of Lipo-JICG (or ICG) with
blood. (b) 800nm PA axial images of TM phantom with insets showing SO2 and Lipo-JICG
(or ICG) images of the target region for 0.9 OD Lipo-JICG/70% SO2 blood (left) and 0.9 OD
ICG/70% SO2 blood (right); color bars for each inset shown on the right. Note that Lipo-JICG
and ICG are readily unmixed in their respective insets; however, there is a large error in SO2
estimation in the phantom with ICG, which is not observed in the phantom with Lipo-JICG.
(c) PA-based SO2 estimation error for all concentration/SO2 combinations tested yield <20%
absolute error for Lipo-JICG (green bars), while yielding nearly 50% error in presence of ICG
(gold bars). (d) Lipo-JICG signal increases by a factor of 3.3 with 3-fold increase in concentration, whereas ICG signal only increases by a factor of 1.4 with 3-fold increase in concentration.
(e) Spectral data from multi-wavelength PA acquisitions in (b) are shown by solid lines (error
bars indicate ±SD across all z-slices), while theoretical spectra for these combinations are
indicated by dashed lines.

36

The wavelength combination used for unmixing was determined by a cost function (Figure 3.2), which included: SO2 estimation error (relative to blood-only samples); error in LipoJICG (or ICG) signal ratio (relative to known 3-fold increase in probe concentration); and number of wavelengths. The cost function optimizes for both the accuracy of Lipo-JICG unmixing
and SO2 estimation, while it includes a modest penalty for the number of unmixing wavelengths used to promote faster acquisition times. The spectral data from each of these multiwavelength PA acquisitions is shown by the solid lines in Figure 3.8e, with the theoretical
spectra for these combinations indicated by dashed lines. Theoretical spectra were calculated
as the superposition of optical absorption spectra of 70% SO2 hemoglobin and 0.9 OD LipoJICG (or ICG); the correlation coefficients between experimental and theoretical spectra were
0.96 and 0.44 for Lipo-JICG and ICG, respectively.
As is shown by both SO2 image insets in Figure 3.8b and the plot in Figure 3.8c, PAbased SO2 estimation error was significantly worse in the presence of ICG, with two ICG
combinations (i.e., 0.9 OD ICG with 50% or 70% SO2 ) yielding >30% absolute SO2 estimation
error; however, it was largely unaffected by the presence of Lipo-JICG, with a maximum absolute error of 18%. The Lipo-JICG signal increased by a factor of 3.3 with a 3-fold increase
in concentration, whereas the ICG signal only increased by a factor of 1.4 with a 3-fold increase in concentration (Figure 3.8d). The less-than-expected ICG signal increase is not due
to nonlinearity of the monomeric ICG PA signal, which Figure 3.7f shows to be quite linear
at the concentrations used, but rather due to the confounding hemoglobin spectra that are
also included while unmixing. Because the absorption peak for monomeric ICG is within the
wavelength range (i.e., ∼750-850 nm) most sensitive for unmixing HbO2 & HHb, it is difficult to
spectrally differentiate ICG from hemoglobin. Thus, some of the increase in PA signal due to
an increase in monomeric ICG concentration gets inaccurately assigned to hemoglobin during
spectral unmixing.
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3.3.3 In vitro evaluation of FRα-Lipo-JICG
Monoclonal anti-FRα antibodies were modified to contain a thiol group on their glycosylated Fc
portion using a hydrazide-PEG-thiol linker [104], which allows binding to maleimide groups on
the surface of Lipo-JICG via a maleimide-thiol reaction. This directional conjugation approach
does not involve antigen-binding Fab portions of anti-FRα antibodies, leaving antigen-binding
sites fully available for interaction with FRα receptors. FRα-targeted Lipo-JICG (FRα-LipoJICG) had the same UV-Vis-NIR spectrum as the maleimide-functionalized Lipo-JICG (MalLipo-JICG) without antibodies (Figure 3.9), which indicates that antibody conjugation does
not affect the absorbance of Lipo-JICG. Furthermore, FRα-Lipo-JICG exhibited a high photothermal stability as there were no changes in its PA spectrum after four consecutive spectral
acquisitions (1,440 total laser pulses) at a maximum fluence of ∼20 mJ/cm2 (Figure 3.10,
left). Conversely, monomeric ICG showed signs of photobleaching as its PA signal intensity
decreased after four consecutive spectral acquisitions (Figure 3.10, right).
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Figure 3.9: UV-Vis-NIR spectrum of antibody-conjugated vs. non-conjugated Lipo-JICG.
FRα-Lipo-JICG (red) has the same UV-Vis-NIR spectrum as non-conjugated Mal-Lipo-JICG
(blue), demonstrating that the antibody conjugation does not affect the absorbance of the
Lipo-JICG nanoparticles.
After conjugation, we labeled high-expressing FRα+ SKOV3 and low-expressing FRαA2780 cells with FRα-Lipo-JICG and carried out PA imaging in a 36-well gelatin phantom (Figure 3.11c); control cells (i.e., without Lipo-JICG) were included to assess background signal.
The 880nm PA signal from SKOV3 cells incubated with FRα-Lipo-JICG was ∼3-fold greater
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Figure 3.10: Photothermal stability of Lipo-JICG vs. ICG. PA spectra of FRα-Lipo-JICG
(left) in PBS and monomeric ICG (right) in 50% EtOH from first irradiation spectral sequence
(360 total laser pulses) and final irradiation sequence (1,440 total laser pulses) demonstrates
that FRα-Lipo-JICG particles provide greater photothermal stability than monomeric ICG.
Correlation coefficients between first and last spectra are 0.99 for both FRα-Lipo-JICG and
monomeric ICG, indicating high agreement between spectral features for both.
than that from labeled A2780 cells (Figure 3.11b,d), which is in good agreement with literature
reports of approximately four times higher expression levels of FRα in SKOV3 vs. A2780 cells
[114, 115]. There was negligible PA signal from control cells.

3.4 Discussion
This project was started with the goal of developing a robust PA contrast agent based on particular specifications that need to be achieved for a successful clinical translation, including:
(i) high absorbance in the NIR optical tissue window; (ii) the possibility of quantitative combined functional (e.g., SO2 ) and molecular PA imaging; (iii) stability during storage and in vivo
applications; (iv) molecular specificity; and (v) reduction of regulatory approval burden. Our
agent, Lipo-JICG, was built around ICG dye because of its optical absorbance in the NIR and
its FDA approval status. Then, Lipo-JICG’s absorbance and PA signal generation were significantly increased by forming J-aggregates that allowed sensitive detection at clinically relevant
depths (Figure 3.8). Further, shifting the absorbance peak to ∼890 nm eliminated overlap
with distinctive spectral features of hemoglobin that are commonly used for blood oxygena-
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Figure 3.11: In vitro evaluation of FRα-Lipo-JICG targeting. (a) Schematic of particle
conjugation shows anti-FRα antibody with heterobifunctional linker on Fc moiety attaching
to maleimide on Lipo-JICG via directional bioconjugation. (b) PA signal spectra for FRα+
SKOV3 (red) and FRα- A2780 (blue) cells labeled with FRα-Lipo-JICG particles with unlabeled
SKOV3 (magenta) and A2780 (cyan) as controls. 880nm PA signal from labeled SKOV3 cells
is ∼3-fold greater than that from A2780 cells with FRα-Lipo-JICG; there was negligible PA
signal from bare cells. (c) Example 3D B-mode US image of 36-well gelatin phantom; cells
were seeded in triplicate for PA assessment. (d) Example of PA-US images for cell inclusions
shows significantly higher 880nm PA signal in SKOV3 cells than in A2780 cells when both are
incubated with FRα-Lipo-JICG. White scale bar indicates 1 mm.
tion measurements. In phantoms, we achieved accurate SO2 estimation and Lipo-JICG signal
(e.g., ∼3-fold increase with commensurate concentration increase) in the presence of blood
due to the inherent separation of hemoglobin and Lipo-JICG spectral features (Figure 3.3).
During systemic delivery, an exogenous agent will often present with a similar (or lower) in40

travoxel optical absorption to that of hemoglobin [116]. Because of its sharp absorption peak
at ∼890 nm, Lipo-JICG lies in a spectral region where hemoglobin absorption spectra are relatively flat. This inherent spectral separation allows for straightforward unmixing of hemoglobin
and Lipo-JICG with high contrast.
ICG J-aggregates in Lipo-JICG were stabilized by liposomal encapsulation with decades of
successful applications in liposomal drug delivery formulations [117]. Lipo-JICG has a mean
diameter of 130 nm, is stable under laser fluences up to 15 mJ/cm2 , shows a linear PA response over concentrations up to 25 OD, and is very stable for 6 hr in serum and for at least
one month under storage conditions. Furthermore, use of functional maleimide lipids in the
formulation of Lipo-JICG enabled robust directional conjugation of monoclonal antibodies for
molecularly specific targeting of tumor cells that overexpress FRα. To this end, we demonstrated successful targeting of PAtrace to the FRα receptor on SKOV3 ovarian cancer cells in
an in vitro setting.
ICG J-aggregates in Lipo-JICG were stabilized by liposomal encapsulation with decades of
successful applications in liposomal drug delivery formulations [117]. Lipo-JICG has a mean
diameter of 130 nm, is stable under laser fluences up to 15 mJ/cm2 , shows a linear PA response over concentrations up to 25 OD, and is very stable for 6 hr in serum and for at least
one month under storage conditions. Furthermore, use of functional maleimide lipids in the
formulation of Lipo-JICG enabled robust directional conjugation of monoclonal antibodies for
molecularly specific targeting of tumor cells that overexpress FRα. To this end, we demonstrated successful targeting of PAtrace to the FRα receptor on SKOV3 ovarian cancer cells in
both in vitro and in vivo settings and observed increased Lipo-JICG CE of targeted FRα-LipoJICG in SKOV3 tumors relative to non-targeted RG-16-Lipo-JICG. Because we demonstrated
Lipo-JICG stability of at least 6 hr in serum and saw significant uptake of FRα-Lipo-JICG 60
min postinjection, probe stability is sufficient for our imaging window. Imaging of FRα in ovarian cancer cells has important implications in developing molecular therapies for FRα blockade
and for longitudinal therapy monitoring in the clinic [115, 118].
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We carefully selected the composition of Lipo-JICG to simplify future clinical translation.
Every major component in the core formulation (i.e., DPPC, DSPE-PEG, DSPE-PEG-Maleimide,
cholesterol, ICG, & anti-FRα antibody) can be sourced from sources compliant with current
Good Manufacturing Practices (cGMP), which is one major hurdle in clinical translation of a
product. Another major barrier to the clinic is the toxicity profiling of each of the components.
If a component is not classified as Generally Regarded as Safe or has not had toxicology or
pharmacology studies under current Good Laboratory Practices (cGLP), then an extensive
amount of preclinical testing is required before clinical testing can occur [119]. Each of LipoJICG’s components either have been already used in a clinical trial or is currently approved
by the FDA. DPPC has made it to Phase III clinical trials in the formulations Stimuvax (Oncothyreon, Inc., R Flourney, CA) and ThermoDox (Celsion Corporation, Lawrenceville, NJ)
[120]. DSPE-PEG has been featured in both FDA-approved Doxil®(Sequus Pharmaceuticals,
Inc., Menlo Park, CA) and OnivydeTM (Merrimack Pharmaceuticals, Cambridge, MA) [120].
DSPE-PEG-Maleimide is currently featured in a Phase I clinical trial of MCC-465 (Mitsubishi
Tanabe Pharma Corporation, Osaka, JP) [120]. Cholesterol is included in the majority of clinical liposome agents, including Doxil®, DaunoXome®(NeXstar Pharmaceuticals, Boulder, CO),
and others [120]. ICG has been FDA approved since 1959 [121]. Finally, anti-FRα antibodies
have been studied in Phase III clinical trials under the name farletuzumab (Morphotek, Inc.,
Exton, PA) [122]. Overall, given the clinical history of these components and their relatively
low toxicities, we would expect a streamlined path for Lipo-JICG through cGMP, cGLP, and a
Phase 1 clinical trial.
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Chapter 4: PA-Based Assessment of SO2 in a Model of ALL
This chapter is adapted from the following published work:
Reprinted, with permission, from C. Wood, K. Harutyunyan, D. Sampaio, M. Konopleva,
R. Bouchard. Photoacoustic-based oxygen saturation assessment of murine femoral bone
marrow in a preclinical model of leukemia. Photoacoustics, 14:31-36, 2019. Open Access
License CC BY-NC-ND 4.0.

4.1 Introduction
A variety of hematological diseases manifest in the bone marrow (BM), broadly characterized
as BM failure (BMF), defined as an abnormality in erythroid, megakaryocytic, and monocyte
cell lineages [123, 124]. In some cases, BMF can be caused by acute lymphoblastic leukemia
(ALL), in which ALL cells engraft in BM, leading to hypoxia-inducible factor 1-alpha (HIF-1α)
induction in the BM niche [125, 126]. This results in an expansion of hypoxic regions, which
allows leukemic cells to infiltrate further, compromising normal hematopoietic cells [127]. Consequently, diagnosis and treatment of many hematological diseases stand to benefit from accurate characterization of BMF through assessment of in vivo oxygenation in the BM.
In vivo PA imaging of SO2 in the femoral BM can provide a label-free technique with high
spatiotemporal resolution for a noninvasive assessment of the BM oxygenation dynamics. Although SO2 is not a direct measure of intracellular hypoxia, it has been shown to be correlated with pimonidazole-assessed hypoxia and pO2 levels proximal to capillaries [49, 50]. This
chapter demonstrates an optimized longitudinal PA imaging technique to probe the oxygenation status of the femoral BM. After verifying that the hemoglobin signatures present in PA
images co-located with the femoral BM cavity via co-registration with x-ray CT, repeated PA
imaging was conducted in control mice to demonstrate the repeatability of this imaging technique across all time-points. Results from a preclinical pilot study of ALL show that temporal
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changes in intrafemoral SO2 correlate with ALL disease progression.

4.2 Materials and Methods
4.2.1 Mouse Model
All animal work was performed in accordance with a protocol approved by the Institutional Animal Care and Use Committee. A transgenic murine leukemic BM cell (LBC) line was generated
from murine Ai14/CD19-Cre BM B-cells that express TdTomato [37]. These cells were retrovirally transduced with the p190/Bcr-Abl oncogene and grown in cell culture for transduction
with the Luciferase retrovirus [37]. 2×105 LBCs were then suspended in PBS and inoculated
intravenously into six- to eight-week-old B6-albino mice (Jackson Laboratory, Bar Harbor, ME).
Engraftment was confirmed with bioluminescence imaging (BLI) at least 2 days post-injection
(Figure 4.1I).

4.2.2 Imaging Acquisition
All PA imaging was performed on the MSOT inVision 256-TF imaging system (iThera Medical,
Munich, DEU), which has a 256-element, 270◦ -arc acoustic-receiver array with 5 laser-fiberbundle pairs for PA signal generation. Images are acquired axially (Figure 4.1B-C), and the
mouse is translated in the z-axis to obtain volumetric data. The wavelengths used in this study
included 715, 730, 760, 800, 850, and 880 nm; at least 10 frame-averages were used for all
acquisitions. Water temperature was maintained at 34◦ C; mice were anesthetized with 1.2%
isoflurane delivered via 100% oxygen at a flow rate of 0.8 L/min. Fur was removed with Nair
prior to imaging, and a thin layer of ultrasound gel was applied to improve acoustic coupling.
Measures were taken to ensure repeatability of animal setup between imaging sessions.
For the first time-point, the mouse was positioned with its hind limbs in the ankle cuffs and
extended as far as reasonable (Figure 4.1A). This position was recorded to place the mouse
in the same location at subsequent time-points. Mice were imaged over a 25 mm volume with
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Figure 4.1: Summary of methods for ALL PA imaging study. (A) Setup for PA imaging in
MSOT inVision 256-TF. Mice are positioned as shown in orange dashed box, then placed in
the scanner for imaging. Scan range is set to include the extent of both femurs (red volume;
middle imaging frame indicated by green outline). Wavelengths were selected based on the
HbO2 and HHb extinction spectra, as shown. Volume stack of PA images with corresponding
noise images at (B),(D) 715 nm and (C),(E) 880 nm. Unmixed axial images with (F) HbO2
and HHb overlaid 800-nm image and (G) SO2 image. (H) SNR-masked SO2 image overlaid
800-nm image. Matched BLI at (I) day 4 and (J) day 11, showing increase in cell engraftment
in femurs as disease progresses. Timeline at the bottom shows imaging time-points, with PA
imaging indicated by blue circles and BLI indicated by green diamonds.
a 0.2 mm step size, resulting in a scan time around 12 minutes; the scan volume included the
full extent of both femurs, with extra frames superior and inferior to ensure the entire femur
was sampled.
After all PA data were acquired, images were reconstructed by iterative reconstruction
using the ViewMSOT software package (v.3.8, iThera Medical). Images were then unmixed
for HbO2 and HHb using linear regression, and voxel-wise SO2 was calculated as the ratio of
HbO2 to total hemoglobin [69]. Unless otherwise stated, reported SO2 values are defined as
the average within a region of interest (ROI) encompassing the noted anatomy (i.e., intra-ROI
mean).
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4.2.3 CT/PA Co-Registration
To verify that observed PA signals originated in the femoral BM, control mice were imaged on
both the MSOT and the AlbiraSi X-ray CT (Bruker, Billerica, MA) imaging systems, verifying
matched animal positioning with anatomical fiducials. 3D PA image data were then manually
co-registered with 3D X-ray CT image data to determine whether the hemoglobin signal visible
in PA images co-located with the BM cavity. Additionally, a noise threshold was applied to
PA images to verify that only pixels with signal-to-noise ratio (SNR) >6 dB were included in
analysis [84].

4.2.4 System Characterization
To determine the optimal imaging parameters, it was necessary to balance scan time with
SO2 estimation precision. Scan time increases linearly with wavelength number and frameaveraging; precision tends to maintain a nonlinear relationship with these parameters. Imagingwavelength combinations (table, Figure 4.3) were assessed with 10-, 15-, and 20-frame averages in a wild-type (“control”) mouse. Optimization was then determined based on the minimum of a cost function:

CF = σ × nAvg 2

(4.1)

where σ is the standard deviation in femoral-artery SO2 (Sa O2 ) estimates (to assess measurement precision) and nAvg is the number of employed frame-averages (weighted more heavily
to minimize scan time for noticeably frail leukemic mice). To obtain σ, four axial locations were
imaged using parameters detailed in 2.2. SaO2 was obtained from an ROI encompassing
the femoral artery; σwas then calculated as the standard deviation of Sa O2 across the axial
locations. The femoral artery was selected for this analysis because it is a known value (i.e.,
the mouse is breathing 100% O2 , so we expect Sa O2 near 100%) and is a clear anatomical
marker in PA images.
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Based on this optimization, three controls were imaged over five time-points (timeline, Figure 4.1) with six wavelengths and 15-frame averaging. Femoral-BM SO2 (Sf O2 ) was obtained
from ROIs placed over femoral BM signals in 800-nm axial PA images. Sf O2 for each mouse
was assessed over the length of the femur (“femoral extent”) for all five time-points; intra-ROI
standard deviation was also calculated to ensure that ROI placement was correct. Then, to
compare Sf O2 across all controls, the intra-cohort mean and standard deviation (Sf O2 and
σSf O2 , respectively) were assessed over the femoral extent for all time-points.
4.2.5 Leukemia Pilot Study
A pilot study was performed to compare temporal differences in Sf O2 between control and
leukemic mice through disease progression. Five mice were inoculated with LBCs, as described in 2.1 (“leukemic”); three were not injected (“controls”). Each mouse was imaged at
five time-points: pre-inoculation, and days 4, 7, 11, and 14 post-inoculation. Controls were
imaged as described in 2.4; leukemic mice were imaged similarly with six wavelengths, but
with 10-frame averaging to reduce imaging time for the frail leukemic cohort. BLI was performed at each post-inoculation time-point to track leukemic cell engraftment. Sf O2 and σSf O2
were compared between cohorts at each time-point; statistical significance was determined
by a two-tailed t-test (α=0.05). Additionally, absolute changes in Sf O2 were assessed relative to baseline for each mouse, and the intra-cohort mean of these changes (|∆Sf O2 |; e.g.,
|Sf O2 Day11 – Sf O2 Day0 |) was assessed; statistical significance was determined by a two-way
repeated measures ANOVA (α=0.05). Day 14 results were excluded from analysis because
leukemic mice had experienced paralysis and >10% loss in body mass, which significantly
confounded Sf O2 measurements.
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4.3 Results
4.3.1 CT/PA Co-Registration
Co-registered PA and CT images of a control mouse demonstrate colocalization of the femoral
PA (i.e., hemoglobin) signal and the CT-delineated BM cavity (Figure 4.2C). The BM PA signal
appears diffuse due to intra-cavity sound reverberation. Additionally, the applied SNR thresh-
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Figure 4.2: Co-registration of PA and CT axial images. (A) Axial PA image in a representative mouse showing 800-nm background (grayscale) with HbO2 (red) and HHb (blue) unmixed
overlay with signal from femoral BM (indicated by teal circles); (B) matched X-ray CT to show
anatomy. (C) Overlay of X-ray CT on PA image shows that the hemoglobin signal seen in the
PA image co-locates with the BM cavity seen on X-ray CT, indicating that the signal originated
in the BM. Femoral arteries are indicated by red circles. (D) SNR-masked SO2 image overlaid
on 800-nm PA image demonstrates that sufficient SNR is achieved in the BM cavity to reliably
estimate femoral SO2 .

4.3.2 System Characterization
Optimized wavelength/averaging combinations were determined based on minima of the cost
function (Eq. 1), which selected 6-wavelength unmixing and either 10- or 15-frame averaging
(red circles, Figure 4.3A). Using these parameters, control mice were imaged over five timepoints to assess temporal variability of Sf O2 . The average of Sf O2 estimates across the femoral
extent and all time-points was 46.1±1.0%. Spatial dependence in Sf O2 is evident across the
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femoral extent: Sf O2 tends to increase towards the distal end (Figure 4.3B,C). This could
be attributed to differences in depths of femoral-BM PA signals as there is more soft tissue
surrounding the proximal end than the distal end. Varying depths could affect the accuracy of
HbO2 and HHb unmixing (due to wavelength-dependent optical attenuation [59]) and therefore
change the calculated Sf O2 . However, day-to-day Sf O2 estimates in each frame showed less
than 2.4% Sf O2 variation in each subject, implying that this effect is temporally stable and thus
allows for longitudinal assessment of other factors, such as disease progression.
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Figure 4.3: PA optimization and control mouse variability. (A) Plot of cost function for all
tested acquisition parameters. Wavelength combinations are shown in the table on the top
right. PA-based (B) Sf O2 for a representative control mouse and (C) (Sf O2 ) for control cohort.
The average (Sf O2 ) across the femoral extent for all time-points are summarized in the table
on the bottom right.

4.3.3 Leukemia Pilot Study
At day 0 in the leukemic cohort, Sf O2 averaged over the femoral extent was 45.8%; at day
11, this reduced to 36.8%. Additionally, leukemic σSf O2 averaged over the femoral extent in49

creased from 5.2% at day 0 to 10.2% at day 11 (shaded regions, Figure 4.4). Neither of these
changes was statistically significant. As BM hypoxia increases, the expectation would be for
Sf O2 to decrease; however, as demonstrated by the high σSf O2 at day 11, some leukemic mice
experienced increased Sf O2 with disease progression relative to baseline, while others experienced decreased Sf O2 . This indicates that although hypoxia and Sf O2 are correlated, they
are not directly related. Sf O2 assesses vascular oxygenation, whereas hypoxia exists further
downstream in the extravascular compartment and can be caused by a variety of biological
effects (i.e., abnormalities in vasculature or sufficient diffusion distance [27]), which cannot be
discerned from Sf O2 assessment alone.
A

B

C

D

Figure 4.4: PA-based Sf O2 in control vs. leukemic mice. PA-based femoral SO2 for control
(blue) and leukemic (red) mice at (A) day 0, (B) day 4, (C) day 7, and (D) day 11. Each line
shows (Sf O2 ) for the cohort, and shaded regions indicate σ(Sf O2 ) for the cohort.
Figure 4.5 shows plots of |∆Sf O2 | across the femoral extent. Statistical significance was
assessed separately in three regions: the proximal end, the femoral body, and the distal end.
There was a statistically significant difference in |∆Sf O2 | between the leukemic and control
cohorts in the femoral body region (asterisks, Figure 4.5). Therefore, it may be necessary
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to measure subject-specific temporal changes in Sf O2 to be sensitive to changes in leukemic
disease progression.
A

*

*

B

C

*

Figure 4.5: PA-based |∆(Sf O2 )| in control vs. leukemic mice. |∆(Sf O2 )| for (A) day 4 – day
0, (B) day 7 – day 0, and (C) day 11 – day 0. There is a statistically significant difference
between controls (blue) and leukemic (red) mice in the middle region of the femur, as indicated
by * (Repeated Measures Two-Way ANOVA; α=0.05), between leukemic and control cohorts.

4.4 Discussion
In future studies, contrast may be further improved by varying oxygen inhalation conditions
(e.g., 100% and 21% O2 ), a method that has been demonstrated in other disease models
[17]. Additionally, Sf O2 measurements at the final time-point could be correlated with hypoxia through immunohistochemical analysis, which is established for this disease model [37].
These studies will help further discern the relationship between |∆Sf O2 | and leukemic disease
progression. PA-based Sf O2 assessment could, in turn, be used as a preclinical assay to assess the efficacy of novel ALL treatments currently under investigation [128]. Furthermore,
this assay could be applied to a variety of BMF applications, particularly aplastic anemia, in
which there is a reduction in hematopoietic production [124]. Although clinical PA-based measurements in BM may be difficult, some sites (e.g., appendages) could be imaged with an
arc-array, which offers an increased receive angle for improved sensitivity [129]. This would be
particularly applicable to pediatric patients, whose bones are thinner and more readily permit
one-way transmission of PA-generated US signal out of the BM cavity [130, 131].
This work presents an optimized in vivo, noninvasive, label-free PA imaging technique for
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Sf O2 estimation, demonstrating a repeated-measure variability of less than 2.4% in a control
cohort. This technique was applied to a pilot cohort of leukemic mice, and temporal changes
in Sf O2 demonstrated a statistically significant correlation with leukemic disease progression.
PA-based Sf O2 imaging is able to reliably assess changes in BM oxygenation status, an emerging imaging biomarker that has potential to provide valuable insight into many hematological
diseases that manifest as BMF.
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Chapter 5: PA-Based Assessment of SO2 and Lipo-JICG in a
Model of Ovarian Cancer
5.1 Introduction
As shown in chapter 3, Lipo-JICG exhibits several properties that are advantageous for in vivo
PA imaging, including: a red-shifted absorbance peak, which facilitates more straightforward
unmixing from endogenous hemoglobin; PA signal enhancement from increases in thermal
gradients and optical absorbance; a PA spectrum that is independent of concentration, allowing for simpler post-processing to achieve quantitative PA imaging; and in vitro molecular
specificity. In this chapter, we build upon this characterization to investigate Lipo-JICG as an in
vivo imaging agent. First, its biosafety was investigated, both via in vitro toxicity with cancerous and normal cells, then in vivo in normal mice through the circulation half-life, hematology,
blood chemistry, and histology of vital organs. PA imaging of Lipo-JICG was then compared
to imaging monomeric ICG in normal mice, with both preclinical PA and clinical PA-US imaging systems, to demonstrate advantages of the J-aggregated form of ICG in the presence of
hemoglobin and at depth. Finally, mice with SKOV3 ovarian tumors were imaged before and
after injection of either targeted FRα-Lipo-JICG or non-targeted RG-16-Lipo-JICG to demonstrate in vivo molecular specificity of Lipo-JICG.

5.2 Methods
5.2.1 In vitro cell toxicity study
A dose-response assay with PEGylated Lipo-JICG (PEG-Lipo-JICG) was conducted to assess cell viability. PEG-Lipo-JICG and monomeric ICG solutions were prepared in fresh cell
culture media with concentrations ranging from 0 to 6.6 OD, where the latter corresponded
to ∼5.9×109 Lipo-JICG nanoparticles/mL. Solutions with empty liposomes were similarly pre53

pared with concentrations ranging from 0.34x to 2.7x of the highest Lipo-JICG concentration
(i.e., ∼1.57×1010 nanoparticles/mL, which corresponds to 6.6 OD). The empty liposomes were
prepared using the same lipid ratios and concentrations as used in Lipo-JICG synthesis (see
“Composition and synthesis of Lipo-JICG” section). SKOV3, A2780, MDA-MB-468, FaDu, 3T3,
and HUVEC cells (ATCC, Manassas, VA) were seeded on 96-well tissue-culture polystyrene
plates at 8,000 cells/well in triplicate of each concentration and incubated overnight at 37◦ C in
5% CO2 . Then, culture media was replaced with solutions of PEG-Lipo-JICG for all cells, and
with ICG or liposomes for HUVEC cells; cells were incubated for another 24 or 48 hr. After
incubation, culture media with Lipo-JICG was removed, and a mixture of 1-part CellTiter 96
Aqueous Nonradioactive MTS (Promega Corporation, Madison, WI) and 5 parts fresh media
was added at 120 µL/well. After incubation for 90 min at 37◦ C in 5% CO2 , absorbance was
measured at 490 nm in the Synergy HT Microplate Reader. Statistical differences between
each sample and the control (i.e., no nanoparticles or ICG) were determined by a two-tailed
two-sample t-test (α=0.05).

5.2.2 In vivo circulation half-life imaging and analysis protocol
To estimate the half-life of FRα-Lipo-JICG in circulation, PA imaging was carried out in the
inVision system (890 nm; 15-frame averaging). PA images were acquired axially over three
z-positions (0.5mm step size) spanning the neck. Baseline 3D PA imaging was performed on
wild-type female athymic nu/nu mice before 100µL intravenous injection of 100 OD FRα-LipoJICG, then mice were imaged continuously for 15 min immediately postinjection. For analysis,
an ROI was manually placed over a superficial surface vein. Analysis was done from the center
of the vessel, which was determined to be the voxel with the maximum sum across time. This
voxel was plotted across time and the data were fit to an exponential as

P A(t) = P A0 e−λt
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(5.1)

where PA0 is the maximum 890nm PA signal, and λ[min-1 ] is the decay constant. The half-life
was then calculated as t1/2 = ln(2)/λ.

5.2.3 Blood assays and histology
To determine in vivo biosafety of FRα-Lipo-JICG, hematology and blood chemistry analysis
and histology of vital organs were performed on wild-type nu/nu mice injected with FRα-LipoJICG (N=5) sacrificed 24 hr postinjection and on one control mouse that was not injected.
Blood samples were collected via cardiac puncture, and samples were analyzed on a Siemens
ADVIA 120 Hematology System (Siemens Medical Solutions USA, Inc., Malvern, PA) and
a Roche COBAS Integra 400 Plus (Roche Diagnostics, Rotkreuz, CH). Blood assays were
evaluated by a veterinarian certified by the American College of Laboratory Animal Medicine.
For histology, the liver, spleen, kidneys, and heart were collected immediately after sacrifice,
and tissues were fixed in formalin for 48 hr before processing with H& E staining. Tissues
were evaluated by a veterinary pathologist certified by the American College of Veterinary
Pathologists.

5.2.4 In vivo comparison of Lipo-JICG to monomeric ICG
For a matched comparison of Lipo-JICG and monomeric ICG in vivo, 100 µL of 0.4mM ICG
was injected intravenously into a nu/nu mouse, and PA imaging was conducted on the inVision
system (710, 734, 760, 800, 830, 870, 890, 900, & 920 nm; 10-frame averaging) in a region
where the aorta and a superficial artery are clearly visible. For all inVision imaging, mice were
allowed to equilibrate in the system for 10 min before imaging. Isoflurane was maintained at
2% with an oxygen flow rate of 1 L/min for all mouse imaging. Once the probe completely
cleared circulation (∼90 min), 100 µL of Lipo-JICG was injected at a matched ICG concentration of 0.4 mM and imaged with the same parameters and in the same anatomical location.
All PA acquisitions were unmixed for HbO2 , HHb, and Lipo-JICG (or ICG); display dynamic
ranges were set to ensure that no preinjection signal from either probe was observed and that
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comparable postinjection intensity of a superficial artery was achieved.
In a separate experiment, 50 µL each of Lipo-JICG and ICG were injected at matched
ICG dye concentrations of 0.01 mM subcutaneously into the mammary fat pad of the same
mouse, and a tissue-mimicking stand-off was placed on top of the mouse to achieve a ∼17mm
imaging depth for both injected probe samples. PA imaging was acquired for both probes
simultaneously with the Acuity system (680-980 nm, 5nm step size). Lipo-JICG (or ICG) was
visualized at its peak wavelength (i.e., 885 nm for Lipo-JICG or 800 nm for ICG) and displayed
over the background B-mode US image; display dynamic ranges were set to ensure that no
preinjection signal from either probe was observed.

5.2.5 Animal model of ovarian cancer
To evaluate the utility of Lipo-JICG for molecularly specific PA imaging in vivo, an orthotopic
model of ovarian cancer was used. All experiments were approved by the Institutional Animal
Care and Use Committee of the MD Anderson Cancer Center. FRα+ SKOV3 cells were grown
and inoculated into mice, as previously described[132, 133]. Female athymic nu/nu mice were
injected with 1×106 cells into the left ovary via intraovarian surgical implantation. Tumors were
allowed to establish over a period of ∼14 days.

5.2.6 In vivo biodistribution imaging protocol
To monitor SKOV3 tumor growth, axial and coronal T2-weighted MR images were acquired
on a 7T Bruker BioSpec (Figure 5.1a; Bruker, Billerica, MA). When tumors reached ∼5 mm
diameter, 3D tomographic PA imaging was carried out using the inVision system (730, 760,
780, 800, 830, 890, & 910 nm; 15-frame averaging; see “In vivo comparison of Lipo-JICG to
monomeric ICG” for other imaging parameters). As shown in Figure 5.1b, PA images were
acquired axially over a range of z-positions that spanned the liver and intraovarian tumor in
0.5mm steps, ensuring that entire tumor volume and multiple control organs (i.e., liver, spleen,
& kidneys) were captured. Baseline 3D PA imaging was performed prior to a 100µL intravenous

56

injection at 100 OD of either FRα-Lipo-JICG (N=3 mice) or non-targeted RG-16-Lipo-JICG
(N=3 mice). Mice were then imaged immediately, 30 min, and 60 min postinjection. As this is
a pilot study, the sample size per group (N=3) was selected as the minimum where we could
reasonably obtain estimates of the mean and variance within each group. These estimates will
be used to inform the design of subsequent follow-up studies.

5.2.7 PA post-processing and ROI selection
For all imaging experiments, “SO2 image” is defined as an image matrix containing the voxelwise ratio of the unmixed HbO2 coefficient to the total hemoglobin (i.e., HbO2 + HHb) [69],
while “SO2 estimate” is a scalar obtained by taking the spatial average of SO2 image over
a given ROI. Similarly, “Lipo-JICG (or ICG) image” is an image matrix containing the voxelwise ratio of unmixed Lipo-JICG (or ICG) coefficient to the sum of the coefficients for all three
chromophores (i.e., HbO2 , HHb, & Lipo-JICG [or ICG]), while “Lipo-JICG (or ICG) signal” is a
scalar obtained by taking the spatial average of Lipo-JICG (or ICG) image over a given ROI.
To improve the accuracy of PA quantification, a wavelength-dependent, surface-fluencecorrection model was implemented [84]. The inVision’s irradiation field was modeled from the
ring geometry, including the wavelength-dependent water absorption, modeled as exponential
attenuation over depth from water absorption [134], and approximate beam divergence, modeled as a superposition of Green’s functions for the photon diffusion equation (Figure 5.2). The
mouse surface was manually segmented on each of the axial PA images, and surface-fluence
correction was applied at each point along the surface mask. A finite element method mesh
(∼8500 triangular elements) was then generated using NIRFAST 9.1 software [135, 136] to
smoothly propagate the surface-fluence correction through the volume. The mesh used average tissue parameters (µa =10 m-1 , µs ’=100 m-1 ) based on literature values [137], which were
set to be constant across wavelength.
To demonstrate improvement in PA quantification achieved with this surface-fluence correction, three preinjection PA images were selected from a representative mouse to show slices
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Figure 5.1: Summary of methods for in vivo PA imaging study. (a) Coronal (top) and
axial (bottom) MR images to monitor tumor growth, and 3D (bottom) MRI data to localize
ovarian tumors in PA images. (b) PA imaging workflow: mice placed in the inVision system
(bottom-left), and system set to PA imaging presets (i.e., wavelengths, averaging; bottom-left).
Preinjection (top-left) PA axial images (800nm shown) were acquired for each wavelength at
z-positions encompassing the liver, spleen, kidney, and tumor. 100 µL of either targeted FRαLipo-JICG or non-targeted RG-16-Lipo-JICG (100 OD) was injected intravenously; photograph
(top-middle) of mouse setup for intravenous Lipo-JICG injection with blue box showing PA
scan length and orange line indicating current axial slice. Postinjection (top-right) imaging was
performed at 3 time-points, allowing for slice-by-slice co-registration. Representative 800nm
(grayscale colormap; anatomical image) with overlaid 890nm (hot colormap) PA images of
matched tumoral cross-section is shown preinjection (bottom-middle) and 60 min postinjection
(bottom-right) to visualize signal enhancement after Lipo-JICG has accumulated. Images were
fluence corrected and linearly unmixed for (c) Lipo-JICG and (d) hemoglobin (to obtain SO2 )
for each z-position and time-point.
through the liver, spleen, and tumor. Because the absorption spectra of hemoglobin has an
almost constant positive slope between 820-910 nm across all SO2 values, it is possible to
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Figure 5.2: inVision field model. Example of a modeled inVision irradiation field based on
the system’s ring geometry (left). The mouse surface is manually segmented (black line, left),
and a finite element method (FEM) mesh (right) is generated for the tissue.
determine a range of acceptable values for the slope of the absorption, and thus the PA spectrum, between two wavelengths, assuming the only absorbers in the image are HbO2 and HHb.
Thus, by estimating the voxel-wise slope in preinjection images from 830-890 nm, we can determine whether the voxel has a PA spectrum that can be accurately unmixed to hemoglobin
with our linear unmixing strategy.
After applying surface-fluence correction, PA images were unmixed via linear regression for
HbO2 , HHb, and Lipo-JICG using all imaging wavelengths (see “In vivo biodistribution imaging
protocol” section), as determined by a cost function, which included change in SO2 estimates
from preinjection to postinjection, preinjection Lipo-JICG signal, and number of wavelengths
(Figure 5.3). The cost function sought to minimize the preinjection Lipo-JICG signal (which
is expected to be zero in the case of perfect unmixing) and minimize the change in the SO2
estimates from the preinjection acquisition to the (immediately) postinjection one in a superficial, 3x3 ROI in the liver. The latter optimization component is based on the assumption that
SO2 in the liver is not expected to change significantly in the ∼14-min window immediately
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prior to and following the Lipo-JICG injection, as blood SO2 would quickly reach equilibrium
(within a minute) following the injection. Thus, significant changes in such pre-to-post SO2 estimates are instead assumed a result of unmixing inaccuracies caused by the newly introduced
Lipo-JICG chromophore.
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Figure 5.3: Cost function for in vivo wavelength selection. Optimized wavelengths for
unmixing of hemoglobin and Lipo-JICG were determined by a cost function (first equation,
bottom; bar plot, left), which included: absolute change in SO2 estimates from preinjection to
postinjection, each within a superficial-liver ROI (second equation, bottom); preinjection LipoJICG signal within the ROI; and the number of wavelengths (nWL), which accounts for the
overall scan time. The change in SO2 and preinjection Lipo-JICG signal are weighted more
heavily than the number of wavelengths, and the cumulative cost function is the summation of
the individual cost-function calculations for one FRα mouse and one RG-16 mouse to choose
an optimized wavelength combination for both probe types. The wavelength combination obtained from the minimum of the cost function is indicated by a red asterisk. Six wavelength
combinations were tested (table, right).

"Lipo-JICG CE image" for a particular time-point is defined as

CE =

P Atraceimagetime−point − P Atraceimagepreinjection
.
P Atraceimagepreinjection
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(5.2)

This metric signifies that any positive Lipo-JICG CE image voxel has a greater Lipo-JICG signal
than the preinjection value, demonstrating the presence of Lipo-JICG in that voxel at that timepoint. Note that “Lipo-JICG CE” is a scalar obtained by taking the spatial average of Lipo-JICG
CE image over a given ROI. For quantitative comparison of the images, ROIs were manually
placed on images encompassing the liver, spleen, and kidneys (i.e., as control organs; 7, 5, &
5 slices each, respectively) and the tumor (5 slices) for each mouse. Tumors were not readily
identifiable in PA images, so the tumor position and size were determined by co-registering the
MRI-established location and size with the 800nm PA imaging volume using the left kidney as a
fiducial, which was clearly visible in both PA and MRI data. Because Lipo-JICG accumulation
was expected to be sparse and focal in the tumor (due to inhomogeneities within the tumor
mass), only Lipo-JICG CE image voxels that exceeded the baseline (i.e., noise) variation were
included in analysis. This baseline variation was determined by calculating the voxel-wise
difference between spatially adjacent preinjection Lipo-JICG images, then taking the mean
and SD of these differences within the tumor ROI. For analysis, Lipo-JICG CE image values
were excluded if they fell within the mean (±SD) of the baseline variation for each mouse.
Finally, SO2 estimates and Lipo-JICG CE were determined in each segmented organ or tumor
volume (e.g., through volumetric tumor ROI) for each mouse at each time-point, as shown
in Figure 5.10. Statistical differences between groups were determined by a one-tailed twosample t-test (α=0.05).

5.2.8 Western blot of SKOV3 tumors
To prepare lysates of snap-frozen tissue from mice, approximately 30mm2 cuts of tumor tissue
were disrupted with a tissue homogenizer and subjected to centrifugation at 13,000 RPM for 30
min in modified RIPA buffer. The protein concentrations were determined using a BCA Protein
Assay Reagent kit (Pierce Biotechnology, Rockford, IL). Lysates were loaded and separated
by Nu-PAGE 4-12% gradient gels. Proteins were transferred to a nitrocellulose membrane by
iBlot (Thermo Fisher Scientific), blocked with 4% bovine serum albumin, and washed with a
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mixture of tris-buffered saline and Tween 20 solutions. Membranes were then incubated at
4◦ C with primary FOLR1 antibodies (Folate Receptor Alpha Polyclonal Antibody, Lifespan Biosciences, Seattle, WA) overnight. After washing, membranes were incubated with horseradish
peroxidase (HRP)-conjugated horse anti-mouse IgG (1:3000; GE Healthcare, Chicago, IL) for
2 hr. HRP was visualized by an enhanced chemiluminescence detection kit (Thermo Fisher
Scientific). Blots were re-probed with an antibody specific for β-actin (0.1 µg/mL; MilliporeSigma) as a loading control. Densitometry was performed using ImageJ 3.0 software. FRα
expression was quantified as the ratio of FOLR1 antibody to β-actin.

5.3 Results
5.3.1 In vitro cell toxicity study
To assess cytotoxicity of Lipo-JICG, we tested four cancer cell lines (i.e., ovarian SKOV3 and
A2780 cells; breast MDA-MB-468 cells; and head and neck FaDu cells), 3T3 fibroblasts, and
normal HUVEC endothelial cells. Cells were incubated with PEGylated Lipo-JICG (i.e., nontargeted) to avoid any potential biological effects that could be associated with a conjugated
antibody. HUVEC cells were chosen as a model of normal cells and were also incubated with
ICG molecules and with empty liposomes to assess cytotoxicity of these individual components. Empty liposomes were evaluated at nanoparticle concentrations ranging from 0.34x to
2.7x of the highest Lipo-JICG concentration (i.e., ∼1.57×1010 nanoparticles/mL, which corresponds to 6.6 OD), and ICG molecules were evaluated using solutions with the same OD
values as Lipo-JICG samples. Note that we started with Lipo-JICG (or ICG) at 6.6 OD, which
is a particularly high dose that was chosen to intentionally derive toxicity. With Lipo-JICG, cells
did not show cytotoxicity below 6.6 OD after 24 hr, and only two cell lines showed some cytotoxicity effect (viability > 63%) below 6.6 OD after 48 hr compared to controls (Figure 5.4). Empty
liposomes did not exhibit any cytotoxicity in HUVEC cells, while ICG showed some cytotoxicity
in HUVEC cells at high ICG concentrations of 3.3 and 6.6 OD for both time-points (Figure 5.5).
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These data indicate that the observed minor cytotoxic effect at high Lipo-JICG concentrations
might be associated with a very high loading of ICG dye molecules inside Lipo-JICG.
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Figure 5.4: In vitro toxicity of Lipo-JICG. Four cancer cell lines, 3T3 fibroblasts, and HUVEC
endothelial cells were incubated with PEGylated Lipo-JICG at varying concentrations for 24 hr
(top) or 48 hr (bottom). All combinations were prepared in triplicate. Student’s t-test was
conducted against the control.
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Figure 5.5: In vitro toxicity of empty liposomes and ICG. HUVEC endothelial cells were
incubated with empty liposomes (top) or monomeric ICG (bottom) at varying concentrations
for 24 hr or 48 hr. The concentration of liposomes was varied from 0.34x to 2.7x the maximum
concentration of Lipo-JICG shown in Figure 5.4. All combinations were prepared in triplicate.
Student’s t-test was conducted against the control.

5.3.2 In vivo biosafety and circulation half-life of Lipo-JICG
Wild-type mice were injected with FRα-Lipo-JICG and imaged in the inVision system to determine the circulation half-life. Then, 24 hr postinjection, mice were sacrificed and processed
for hematology, blood chemistry, and histology. To measure circulation half-life, mice were
imaged continuously through the neck before and for 15 min after intravenous injection of
FRα-Lipo-JICG. The 890nm PA signal from a superficial surface vein was plotted across time
and fit to an exponential to yield a circulation half-life estimate of 10 (±3.5) min (Figure 5.6). As
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was determined by a board-certified veterinarian, hematology (Table 5.1) and blood chemistry
(Table 5.2) results show no evidence of toxicity as a result of FRα-Lipo-JICG injection. Additionally, no morphologic changes related to the FRα-Lipo-JICG injection are observed in H&E

890nm PA Enhancement [a.u.]

890nm PA Enhancement [a.u.]

samples of liver, spleen, kidney, and heart tissue (Figure 5.7).
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Figure 5.6: Circulation half-life of FRα-Lipo-JICG. Circulation half-life plots from the four
mice injected with FRα-Lipo-JICG and imaged continuously for ∼15 min postinjection. 890nm
data were subtracted from the preinjection baseline to determine enhancement, and an ROI
was selected in a superficial surface vein in the neck. Each mouse was fit to an exponential,
yielding an average (±SD) circulation half-life estimate of 10.0 (±3.5) min.
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Figure 5.7: Representative histology images. Samples of liver, spleen, kidney, and heart
were harvested from five mice injected with FRα-Lipo-JICG (left) and one control mouse that
was not injected (right). Samples were formalin-fixed, paraffin-embedded, stained with H&E,
and examined microscopically by a board-certified veterinary pathologist, Dr. Elizabeth Whitley. There were no observable morphologic changes related to the FRα-Lipo-JICG injection in
any of the samples. Black scale bar to the bottom-right of each image indicates 100 µm.

5.3.3 In vivo comparison of Lipo-JICG to monomeric ICG
Visualization of Lipo-JICG and monomeric ICG was compared in vivo with both the inVision
and the clinical MSOT Acuity PA-US imaging systems (iThera Medical). Briefly, matched ICG
concentrations of each probe were injected intravenously into a mouse and imaged with the
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Table 5.1: Hematology. Hematology results from five mice injected with FRα-Lipo-JICG and
one mouse that was not injected (control). Blood was harvested 24 hr postinjection. The hematology values for the FRα-Lipo-JICG group follow closely with the control, and no significant
changes are noted between the control and FRα-Lipo-JICG groups. According to evaluation by
the board-certified veterinarian, Dr. Jody L. Swain, there was slight hemolysis seen in several
of the FRα-Lipo-JICG samples, which accounts for the modest increase in platelet counts.

WBC (103 /µL)
RBC (106 /µL)
Hgb (g/dL)
Hct (%)
MCV (fL)
MCH (pg)
MCHC (g/dL)
Platelets (103 /µL)
Neut (103 /µL)
Lymph (103 /µL)
Mono (103 /µL)
Neut (%)
Lymph (%)
Mono (%)

Mouse 1
3.36
9.47
14.8
46.7
49.3
15.7
31.8
1413
1.28
1.68
0.2
38
50
6

Mouse 2
3.6
9.21
14.8
45.9
49.9
16
32.1
1290
2.34
0.92
0.08
65
25.6
2.2

Mouse 3
2.93
8.85
14.7
45
50.8
16.6
32.6
1309
1.14
1.61
0.06
39
55
2

Mouse 4
5.17
10.11
16.2
48
47.5
16.1
33.8
1413
3.35
1.49
0.14
64.8
28.9
2.7

Mouse 5
3.15
9.26
14.7
45.9
49.6
15.9
32.1
1289
1.51
1.41
0.04
48
44.8
1.4

Control
4.22
7.78
12.4
38.9
50.1
15.9
31.7
790
1.76
1.53
0.18
41.8
36.4
4.3

preclinical inVision system. Both unmixed chromophores (i.e., Lipo-JICG or ICG) could be
readily visualized in a superficial artery; however, in the aorta (i.e., ∼8mm depth), only LipoJICG was visible with matched dynamic range settings (Figure 5.8).
In a separate experiment, matched concentrations of each probe were injected subcutaneously into the mammary fat pad of a mouse and imaged with the clinical Acuity PA-US
imaging system. Lipo-JICG was clearly visible at >1.5 cm depth through a tissue-mimicking
stand-off, while almost no evidence of monomeric ICG was present for matched molar concentration and injection conditions (Figure 5.9).

5.3.4 Molecular PA imaging of an ovarian cancer model
Mice with orthotopic SKOV3 ovarian tumors were imaged in the inVision system when tumors
reached ∼5 mm in diameter, as confirmed by MRI (Figure 5.1a). Preinjection images (Fig-
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Table 5.2: Blood chemistry. Blood chemistry results from five mice injected with FRα-LipoJICG and one mouse that was not injected (control). Blood was harvested 24 hr postinjection.
The blood chemistry values for the FRα-Lipo-JICG group follow closely with the control, and
no significant changes are noted between the control and FRα-Lipo-JICG groups. According
to evaluation by the board-certified veterinarian, Dr. Jody L. Swain, there was slight hemolysis
seen in several of the FRα-Lipo-JICG samples, which accounts for the modest increase in AST
and LDH values.

Albumin (g/dL)
ALP (U/L)
ALT (U/L)
AST (U/L)
BUN (mg/dL)
Calcium (mg/dL)
Chloride (meq/L)
Creatinine (mg/dL)
Globulin (g/dL)
Potassium (meq/L)
LDH (U/L)
Sodium (meq/L)
Phosphorus (mg/dL)
Glucose (mg/dL)
Total Protein (g/dL)

Mouse 1
3.41
61
29
113
19.8
9.8
110.6
0.24
1.19
4.53
794
149.8
6
128
4.6

Mouse 2
3.15
53
50
172
27
10.4
113.8
0.21
1.01
3.34
900
154.4
7.6
184
4.15

Mouse 3
3.25
75
34
83
23.8
10
113.1
<0.2
0.99
3.49
165
151.1
6.6
279
4.24

Mouse 4
3.15
61
42
162
34
9.8
114.9
<0.2
1.17
3.62
1639
156.8
6.6
116
4.32

Mouse 5
3.23
68
29
138
28.7
10.8
109.5
<0.2
1.19
4.67
336
151.4
8.8
144
4.42

Control
2.54
55
24
96
26.5
9.9
113.8
<0.2
1.55
4.5
346
148.5
6.1
148
4.08

ure 5.1b, top-left) were acquired with the established PA-imaging presets (Figure 5.1b, bottomleft) for each wavelength at z-positions encompassing the liver, spleen, kidney, and tumor.
Targeted FRα-Lipo-JICG or non-targeted RG-16-Lipo-JICG was injected intravenously (Figure 5.1b, top-middle), and 3D PA imaging was repeated at multiple time-points postinjection
(Figure 5.1b, top-right). Monoclonal RG-16 antibodies were used as a non-targeted control because they do not interact with any mouse or human epitopes. PA images were reconstructed
in the ViewMSOT software (iThera Medical), then imported to MATLAB R2019b (MathWorks,
Natick, MA) for post-processing. This included surface-fluence correction to account for variation in the inVision irradiation field, which was modeled from the ring geometry to include
wavelength-dependent water absorption and approximate beam divergence (Figure 5.2). To
smoothly propagate the surface-fluence correction through the volume, the mouse surface was
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Monomeric ICG

Lipo-JICG

Aorta (~8 mm)

Superficial Artery

Figure 5.8: In vivo PA imaging comparison of ICG and Lipo-JICG with preclinical system. Comparison of Lipo-JICG and monomeric ICG in a wild-type mouse with the inVision
preclinical PA imaging system. Each was injected intravenously at the matched ICG concentration of 0.4 mM and identified in vasculature, both superficially in an artery (yellow box) and
at depth in the aorta (cyan box). Superficially (bottom panels), both monomeric ICG (left) and
Lipo-JICG (right) are easily identifiable; however, at depth (top panels), Lipo-JICG is easily
resolvable, while monomeric ICG is not.
manually segmented, and a finite element method mesh was generated using average tissue
parameters, which were set to be constant across wavelength.
Because hemoglobin absorption has a predictable slope from 830-890 nm for all SO2 values, we compared the slope from 830-890 nm in preinjection PA images to determine whether
the surface-fluence correction improved PA-based estimation of hemoglobin distribution in representative images of the liver, spleen, and tumor. The uncorrected images (Figure 5.10, middle panel) show mostly more negative slope than hemoglobin absorption (i.e., blue color map),
particularly in the ROIs of each organ. However, once the surface-fluence correction is applied
(Figure 5.10, right panel), all three organs show significantly more PA slope matching that of
hemoglobin absorption (i.e., green color map).

69

In vivo imaging at depth

a

Photo of subcutaneous injections

b

Acuity Transducer

1cm TM
stand-off

c

Front
schematic

Side
schematic

d

Transducer
TM stand-off

ICG
Lipo-JICG
800 nm 885 nm

TM stand-off

1cm TM
stand-off

PA-US image
TM stand-off support

Figure 5.9: In vivo PA imaging comparison of ICG and Lipo-JICG with clinical system.
Comparison of Lipo-JICG and monomeric ICG in a wild-type mouse with the Acuity clinical PAUS imaging system. (a,c) To image at depth, a 1cm tissue-mimicking (TM) standoff was placed
between the mouse and the transducer. (b) Monomeric ICG and Lipo-JICG were injected
subcutaneously at the matched ICG dye concentration of 0.01 mM and imaged with the Acuity
system; (d) each absorber was visualized at its peak wavelength. Lipo-JICG (green) is easily
resolvable at depth, whereas monomeric ICG (yellow) is much more difficult to distinguish.
Fluence-corrected PA images were then linearly unmixed for Lipo-JICG (Figure 5.1c) and
hemoglobin (i.e., to assess SO2 ; Figure 5.1d) with a wavelength combination chosen by a
cost function (Figure 5.3), which included change between SO2 estimates from preinjection to
postinjection, preinjection Lipo-JICG signal, and number of wavelengths; then, 3D ROIs were
manually ascribed to tumor and liver volumes based on MRI (Figure 5.11a,d) and preinjection
800nm PA imaging (Figure 5.11b,e) data. Postinjection Lipo-JICG accumulation was quantified
by Lipo-JICG Contrast Enhancement (CE) relative to preinjection (see “PA post-processing and
ROI selection” section). SO2 and Lipo-JICG CE images were compared voxel-wise across all
time-points to capture local changes through time.
As seen in Figure 5.11c,f, substantial Lipo-JICG CE from both targeted and non-targeted
Lipo-JICG appeared at the MRI-confirmed tumor location immediately postinjection. This Lipo70
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Figure 5.10: Validation of surface-fluence correction in representative mouse. The PA
slope from preinjection images at 830 and 890 nm was compared with hemoglobin absorption
in the same wavelength range to determine whether PA-based estimates could accurately unmix to hemoglobin. Slices through the liver (top), spleen (middle), and tumor (bottom) were
selected from 800nm images (left panel). Slope images are shown with three colormaps:
blue, indicating a slope more negative than hemoglobin absorption; green, indicating an acceptable slope; and red, indicating a slope more positive than hemoglobin absorption. In the
uncorrected images, all ROIs show mostly a more negative 830-890nm slope (middle panel);
however, after correction is applied, most of the voxels within each ROI are green, indicating
that the PA slope agrees with that of hemoglobin absorption spectra.
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Figure 5.11: In vivo PA imaging specificity of targeted FRα-Lipo-JICG in orthotopic ovarian cancer model. Results for targeted FRα-Lipo-JICG (red) and non-targeted RG-16-LipoJICG (green). Representative (a,d) axial MRI and (b,e) 800nm PA image of SKOV3 tumors with
ROIs indicated by red/green ellipses. MRI volumes were used to establish position and size
of tumors in PA images for ROI placement. Representative Lipo-JICG Contrast Enhancement
(CE) images thru postinjection time-points of (c) targeted FRα-Lipo-JICG and (f) non-targeted
RG-16-Lipo-JICG. (g) PA-based SO2 estimates for liver (left), spleen (middle), tumor (right)
ROIs show that SO2 does not change significantly through time, indicating no substantial physiological changes occurred during imaging. (h) Lipo-JICG CE in liver (left) and spleen (middle)
ROIs suggest no significant difference between FRα-Lipo-JICG and RG-16-Lipo-JICG liver
or spleen accumulation. Lipo-JICG CE in tumor ROIs (right) presents positive enhancement
for both targeted and non-targeted Lipo-JICG immediately postinjection, but with targeted enhancement significantly greater 30 min (p=0.017) and 60 min (p=0.044) postinjection.
JICG CE is most likely associated with the agent in the blood pool. Thirty min postinjection,
however, Lipo-JICG CE was significantly greater (Figure 5.11h, right; p=0.017) for FRα-LipoJICG than for RG-16-Lipo-JICG, and this persisted at 60 min postinjection (p=0.044), indicating molecular specificity of the agent. FRα expression in SKOV3 tumors was confirmed by
Western blotting of excised tumor tissue (Figure 5.12). Lipo-JICG CE associated with both
FRα-Lipo-JICG and RG-16-Lipo-JICG accumulation was observed in the liver (Figure 5.11h,
left) and spleen (Figure 5.11h, middle) across all time-points and did not significantly differ
between targeted and non-targeted Lipo-JICG; this is an expected result for nonspecific uptake of nanoparticles with similar composition by the reticuloendothelial system. There was
no Lipo-JICG CE observed in the kidneys at any time-points, indicating that Lipo-JICG is not
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cleared renally, as has been observed with particles of monomeric ICG encapsulated in liposomes [138]. SO2 was also assessed across all time-points to ensure that no significant
physiological changes occurred during imaging. As shown in Figure 5.11g, SO2 estimates in
the liver (left), spleen (middle), and tumor (right) did not change significantly through time for
a given mouse. Although there was significant inter-tumor SO2 variation observed, which is
expected due to variations between tumors [139], there existed relatively low longitudinal SO2
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Figure 5.12: Western blot of SKOV3 tumors. FRα expression was assessed for each SKOV3
tumor with western blotting of the FOLR1 antibody (left). β-actin was used as a loading control.
FRα expression is quantified as the ratio of FOLR1 to β-actin (right).

5.4 Discussion
As discussed in Chapter 3, Lipo-JICG was developed as a PA contrast agent due to its high
optical absorbance, the possibility to combine functional SO2 imaging with molecular imaging
of cell receptor expression, stability in in vivo imaging applications, and reduced FDA regulatory burden. In this study, we demonstrated accurate SO2 estimation and Lipo-JICG signal
in an in vivo setting (Figure 5.8), which confirms the spectral separation between hemoglobin
and Lipo-JICG observed in phantoms. Again, the inherent spectral separation of hemoglobin
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and Lipo-JICG allows for straightforward unmixing with high in vivo contrast. In turn, these
image data require only a simple post-processing strategy, which corrects for surface-fluence
variation and removes voxels below baseline variation, to provide accurate and concurrent
quantification of both hemoglobin and Lipo-JICG.
An additional goal of Lipo-JICGs was high molecular specificity. In Chapter 3, this was
demonstrated in an in vitro setting; in this in vivo study, we demonstrated successful targeting
of PAtrace to the FRα receptor on SKOV3 ovarian cancer cells in an orthotopic in vivo model
and observed increased Lipo-JICG CE of targeted FRα-Lipo-JICG in SKOV3 tumors relative
to non-targeted RG-16-Lipo-JICG (Figure 5.11). Additionally, because we demonstrated LipoJICG stability of at least 6 hr in serum and saw significant uptake of FRα-Lipo-JICG 60 min
postinjection, probe stability is sufficient for our imaging window. Imaging of FRα in ovarian
cancer cells has important implications in developing molecular therapies for FRα blockade
and for longitudinal therapy monitoring in the clinic [115, 118]. To our knowledge, this is the
first study to successfully image a specific molecular target using a PA contrast agent that is
based on stable dye aggregates. This is significant because dye aggregates provide superior
PA-signal-generation ability and stability relative to individual dye molecules, two critical features that can be leveraged for improved imaging sensitivity and depth penetration. Further,
absorbance peaks of dye molecules that are commonly used in preclinical studies and clinical
trials significantly overlap with distinctive spectral features of hemoglobin that, as our study
demonstrates, can adversely affect quantitation of PA imaging data.
To use this technology in monitoring disease progression and treatment response, it will
be essential to perform PA imaging with repeat injections at multiple time-points. Currently,
the gold standard for monitoring disease progression is through observation of anatomical
changes, such as tumor volume. However, molecular changes – such as an increase in cell
receptor expression – have been shown in many studies to be earlier markers of disease
progression, allowing for more timely treatment strategies [2]. The non-ionizing nature of PA
imaging makes repeated acquisitions feasible, while its limited in vivo stability (i.e., significant
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spectral changes observed at 48 hr in serum) make Lipo-JICG amenable to repeated injections
for longitudinal monitoring of disease or response to therapy. Although this study investigates
PA imaging of Lipo-JICG for FRα+ SKOV3 ovarian cancer, this technology can be applied
to a variety of cell receptors (e.g., epidermal growth factor receptor) and cancer cells that
are accessible with PA imaging. For example, FRα-Lipo-JICG could be used to image triplenegative breast cancer, a subtype of invasive breast cancer with a particularly poor prognosis
and that has been shown to overexpress FRα [140–142].
Additionally, liposomes have been extensively researched as nanocarriers for drug delivery as they allow for targeted delivery of chemotherapeutics while reducing toxicity to normal organs [143], with a few such formulations having already made it into the clinic (e.g.,
PEGylated liposomal doxorubicin, such as Doxil®, for various cancer treatments) [117]. However, one of the key roadblocks in development of such next-generation, liposome-mediated
drug delivery is determining how each liposomal formulation will affect blood circulation, biodistribution, biodegradation, and toxicity [117]. Because of our agent’s liposomal formulation, it
is feasible that Lipo-JICG could be used as a nearly identical surrogate to predict pharmacokinetics of liposome-encapsulated therapeutics with high accuracy [144, 145]. Further, it
has been recently demonstrated in a subcutaneous tumor model that liposomes with encapsulated monomeric ICG can be used to visualize probe extravasation in real time using PA
imaging [146]; this study suggests that it may also be possible to encapsulate a therapeutic
agent in Lipo-JICG and use PA imaging to track its delivery to a desired ROI [147] or to monitor
the agent extravasating in real time.
In conclusion, we have developed and validated a novel PA contrast agent, Lipo-JICG,
starting from a set of aforementioned clinically critical specifications. Lipo-JICG provides
strong PA signal generation that can be readily differentiated from endogenous hemoglobin,
allowing for high-contrast molecular imaging combined with quantitation of physiological parameters, such as blood oxygenation. Lipo-JICG is also – to our knowledge – the first PA
contrast agent with stable dye aggregates that is conjugated with targeting moieties for cell75

specific imaging and can be composed of all FDA-approved components. Overall, Lipo-JICG
has a combination of properties that can facilitate the emergence of molecular PA imaging as
a real-time imaging modality for in vivo visualization of molecular and functional processes in
a clinical setting.
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Chapter 6: Conclusions
6.1 Summary of Findings
Molecular imaging is emerging as a key diagnostic tool to identify and localize disease before
changes in anatomy can be observed. Through the noninvasive assessment of biomarkers,
molecular imaging is capable of probing physiological processes in vivo, which can help facilitate both specialized diagnosis and personalized therapeutic strategies. While there are many
molecular imaging strategies being developed, one of the most promising translational strategies is photoacoustic (PA) imaging due to its nonionizing nature and potential for quantitative,
real-time assessment of imaging biomarkers. In this dissertation, I investigated two imaging
biomarkers for PA imaging: blood oxygen saturation (SO2 ) and cell receptor expression.
Although SO2 was selected as an endogeous biomarker due to its (somewhat convoluted)
relationship to hypoxia, which is associated with increased tumor aggressiveness and resistance to therapy, SO2 has proven to be an imaging biomarker in its own right. Specifically,
in a preclinical model of acute lymphoblastic leukemia (ALL), which manifests with hypoxic
niches in the femoral bone marrow, a significant difference in temporal changes in SO2 (relative to baseline) were observed in leukemic mice relative to control mice. Previously, these
changes in bone marrow oxygenation were only observed with ex vivo assays (i.e., pimonidazole immunohistochemistry) and highly invasive in vivo assays (i.e., multiphoton intravital microscopy), which could only be observed at a single time-point in each subject. With PA imaging of femoral SO2 , we demonstrated a method that can noninvasively monitor the femoral
oxygenation status through time in a single subject, which can allow for noninvasive, label-free
monitoring of diseases that manifest as hypoxic.
To assess cell receptor expression, a novel nanoparticle, Lipo-JICG, was developed, characterized, and tested in phantom, in vitro, and in vivo environments. Because specific cell
receptors, such as folate receptor alpha (FRα), are commonly overexpressed in cancer sub77

types, a noninvasive assessment of cell receptor expression can localize particularly aggressive regions of the tumor and guide a patient-specific treatment strategy. In this project, LipoJICG was conjugated with either targeted FRα or non-specific RG-16 antibodies; then, conjugated Lipo-JICG nanoparticles were injected in ovarian tumor-bearing mice and PA images
were acquired at multiple time-points postinjection. In tumor ROIs, we observed increased
Lipo-JICG contrast enhancement of targeted FRα-Lipo-JICG relative to non-targeted RG-16Lipo-JICG, indicating successful targeting to the FRα receptor on the SKOV3 ovarian cancer
cells. This study demonstrated that Lipo-JICG is a stable contrast agent with the ability for cellspecific imaging, allowing PA imaging to be used as a noninvasive, real-time imaging strategy
to visualize molecular processes in vivo.

6.2 Advances in Knowledge
Through this work, several advances in knowledge have been presented. First, while multiple
studies have compared SO2 with disease progression and treatment response, most of these
prior studies only performed single time-point imaging in each subject [14, 15]. Because one
of the key advantages of PA imaging is the ability to easily and safely repeat imaging in the
same subject, this study investigated imaging the same mouse over multiple time-points to
compare how their disease progression compared with SO2 changes. Although PA-based
SO2 estimates varied significantly more in leukemic mice through disease progression than
in control mice imaged at the same time-points, the femoral SO2 variation across subjects
also increased across leukemic mice. Instead, a higher sensitivity to disease-based changes
was observed via a comparison to each subject’s baseline: ∆SO2 was significantly higher in
leukemic mice than in control mice, indicating the importance of comparing subject-specific
measurements through time to be sensitive to changes in disease progression.
In numerous prior studies, PA imaging-based analysis of biomarkers is averaged over an
ROI, either single-slice or volumetric [14, 148, 149]. However, because PA imaging provides
voxel-wise estimates of chromophore distributions, it has a key advantage in assessing spatial
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variability, which can give a noninvasive assessment of tumor heterogeneity. To this end,
this work investigated strategies to visualize spatial variability in both the ALL and ovarian
cancer models. With ALL, the significant differences in ∆SO2 between leukemic and control
mice were observed in the femoral body, but not in the proximal or distal ends, indicating
that the preservation of spatial information may be necessary to monitor these changes in
disease progression. In PA imaging of FRα-Lipo-JICG in ovarian cancer, spatial heterogeneity
is evident in images of the tumor, both within a single slice and through the volume, indicating
that FRα expression is not homogeneous throughout the tumor. To take this into account in
the analysis of Lipo-JICG contrast enhancement (CE), only Lipo-JICG CE voxels exceeding
the baseline variation (i.e., variation in spatially adjacent preinjection Lipo-JICG images) were
analyzed. Because this spatial variation is evident in the PA images, these could be leveraged
in a clinical setting to guide physicians to regions of the tumor that likely have the highest-grade
disease, either for a biopsy sample or for improved treatment.
PA imaging has the potential to be a valuable clinical assay due to its ability to visualize
physiological processes noninvasively. However, its value would increase significantly with the
ability to also provide a quantitative assessment of imaging biomarkers. In traditional linear
unmixing algorithms, the PA signal is assumed to be proportional to only the optical absorption
coefficient. This results in PA images giving only a qualitative map of the imaging biomarker
because heterogeneities in both the Grüneisen coefficient and local fluence are ignored. Although the inverse problem for estimating optical absorption coefficients from multi-wavelength
PA data would include all spatial- and wavelength-dependent heterogeneities, this problem is
ill-defined and difficult to solve without complex modeling and iterative techniques, which are
being investigated by a multitude of research groups [51, 73, 84, 150]. In this work, a simple
fluence-correction algorithm was employed whereby the imaging system’s irradiation field was
modeled from its geometry, including the wavelength-dependent water absorption and beam
divergence. After segmenting the surface of the imaging subject, a surface-fluence correction, with both wavelength and spatial dependence, was applied to the image and propagated
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through the volume via a finite element method modeling. This strategy of fluence correction
allows for an improvement in the quantification of PA images (i.e., "semi-quantitative" analysis)
without requiring significant time and/or computing resources for the correction, which would
be critical if more complex iterative techniques were applied instead.
To image cell receptor expression noninvasively, an exogenous imaging agent is required.
Many inorganic contrast agents (e.g., gold or silver nanoparticles) have been introduced for
PA imaging with high success in ex vivo settings due to their high absorbance coefficients and
tunable optical properties, allowing for high PA signal generation [92–94]. However, many of
these agents have in vivo toxicity concerns and are made of materials that lack FDA approval,
resulting in a high barrier to clinical translation. Organic contrast agents (e.g., organic dyes)
are widely available and some are FDA-approved for other indications (e.g., ICG for opthalmic
angiography); however, they typically have a low molar absorptivity, which makes generation
of sufficient PA signal challenging [87]. This work introduces an exogenous PA imaging agent,
Lipo-JICG, that addresses both concerns. First, it is composed of materials that can all be
sourced from FDA-approved components, significantly reducing the barrier to clinical translation compared to other agents. One of these components is ICG, which is encapsulated in a
liposome at a high enough concentration to form J-aggregates, which significantly increases
the PA signal due to both a narrowed absorption peak and increased thermal gradients due
to the tight configuration of the absorbers. These features, which have previously not been
achieved in a single PA contrast agent, have been shown in this work to facilitate quantitative
molecular PA imaging in an in vivo application, with promise for clinical translation in the near
future.
In many implementations of PA imaging with an exogenous probe, endogenous absorbers,
particularly hemoglobin, are largely ignored [11, 147, 149]. However, because all in vivo applications of PA imaging will inherently include significant hemoglobin signal, it is imperative to
include a concurrent assessment of HbO2 and HHb with the exogenous probe. In this work,
SO2 and Lipo-JICG were concurrently assessed in both phantom and in vivo settings to de80

termine the accuracy of PA-based estimates of SO2 and Lipo-JICG. This analysis allowed us
to not only demonstrate our ability to assess cell receptor expression noninvasively with LipoJICG, but also to concurrently monitor SO2 through all time-points, which can be leveraged to
monitor tumor microenvironment regularization [106].

6.3 Limitations
As with all optical methods, PA imaging has inherent depth limitations due to absorption and
scattering of photons over depth. PA does not require ballistic photons, allowing for at least
an order of magnitude increase in penetration depth over other optical modalities; however,
PA imaging can still only reach up to a few centimeters, which is significantly less imaging
depth than clinical modalities like CT or MRI. The tomographic laser illumination/acoustic receive strategy used for MSOT imaging can increase PA imaging depth because the signals
are both generated and received from multiple angles, increasing the sensitivity of PA detection. Nevertheless, this will not increase the imaging depth significantly beyond the inherent
limit of photon propagation through the medium. Many strategies are being investigated to
increase PA imaging depth, via both imaging acquisition hardware and parameters as well as
post-processing techniques, but this is currently a significant limitation for a high volume of
translation of PA imaging to the clinical setting.
Additionally, although multi-wavelength PA imaging is necessary to identify different chromophores present in the imaging volume, this presents its own set of challenges. The primary
concern is spectral coloring due to lower wavelengths of light being attenuated more than
higher wavelengths, resulting in a red-shift of the spectrum over depth. In this work, we employed a surface-fluence correction technique to take some of these effects into account; however, this strategy only allows for a semi-quantitative analysis of SO2 and Lipo-JICG. While this
is acceptable in certain implementations - for example, looking at variation in the same subject
through time - it will be necessary to implement more advanced fluence correction techniques
(e.g., a numerical modeling approach) if truly quantitative PA data are needed for a specific
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application.
A further limitation of this work is the imaging site for the ALL study. Because this work
was done in a murine model, the femoral bone was thin enough for light to penetrate and generate an acoustic signal, which was then able to escape the bone marrow cavity. However,
in a clinical setting, imaging through bone with an US-mediated modality would be incredibly
challenging. As discussed previously, it could be possible with an arc array, allowing for tomographic imaging with increased sensitivity; however, this would likely only be possible in
pediatric patients with thinner bones. With current PA imaging techniques, it is likely that this
specific imaging site will be more useful as a preclinical assay to noninvasively assess disease progression and treatment response in diseases (like ALL) that present with oxygenation
changes in the bone marrow.
Finally, although FRα expression in SKOV3 ovarian tumors was confirmed with an independent ex vivo assessment via Western blotting, this assay cannot validate the spatial inhomogeneities observed with PA imaging. Other ex vivo assays (e.g., pimonidazole immunohistochemistry to confirm hypoxia) preserve spatial information; however, they are nearly impossible
to accurately co-register with PA imaging data, and typically only a small region is analyzed
due to the labor-intensive histological processing. Before PA imaging can be reliably used for
quantitative assessment of biomarkers, each will need to be independently validated.

6.4 Future Work
This project has laid the groundwork for developing a PA-based platform for noninvasive molecular imaging of SO2 and cell receptor expression. However, there is more validation and development needed before this platform can be translated clinically. First, as mentioned previously,
independent assays of each biomarker are needed to validate the PA estimates shown in this
study. Although most standard ex vivo assays (e.g., histology or Western blotting) either do
not preserve spatial information or are incredibly challenging to co-register with in vivo imaging
data, there is an emerging preclinical ex vivo imaging system, Xerra cryo-fluorescence tomog82

raphy (Emit Imaging, Boston, MA), which combines whole-body white light and fluorescence
imaging to provide inherently co-registered anatomical and functional images [151, 152]. This
system could be leveraged in multiple ways. First, by conjugating a fluorophore to the surface
of Lipo-JICGs, we could localize uptake of Lipo-JICG nanoparticles via fluorescence imaging
of the fluorophore and compare to PA imaging. Additionally, by imaging in the ICG fluorescence
band, it would be feasible to observe clearance pathways of Lipo-JICGs after the particles have
broken down and ICG has de-aggregated. This whole-body visualization of Lipo-JICG biodistribution could provide additional validation of the chromophore distribution observed with PA
imaging and could potentially provide more insight into other regions to image with PA as well.
With the recent premarket FDA approval of Seno Medical’s Imagio Breast PA-US Imaging
System (Seno Medical, San Antonio, TX) [153], the clinical translation of PA imaging, particularly for visualization of endogenous absorbers, is becoming a reality. However, a primary concern is how PA-US imaging will be integrated into current clinical workflow: without a feasible
strategy for clinical translation for this technology, it is unlikely to achieve significant clinical use.
In this project, we have demonstrated significant diagnostic value that could be added with the
implementation of PA imaging with simultaneous SO2 and Lipo-JICG quantification. Moving
forward, this project must investigate strategies to implement simultaneous imaging of endogenous and exogenous absorbers in a manner that will be straightforward to implement clinically.
For example, in current clinical US imaging, clinicians are accustomed to seeing the images
in real-time. Although PA images can be acquired and unmixed in real-time, it is not currently
feasible to also apply real-time fluence correction, which will likely be necessary for quantitative PA imaging. Real-time fluence correction will likely require a simpler fluence-correction
strategy, such as the surface-fluence-correction method introduced in chapter 5; it may be
possible to optimize the input parameters for different tissue or organ types, which could then
be selected by the sonographer during the exam, to provide such real-time correction. More
complex correction techniques, which require significant time and/or computing power, could
also be implemented in post-processing of images; these would likely require more effort to
83

demonstrate the value of extensive post-processing of images to clinicians, which could possibly be achieved through preclinical and/or clinical observer studies comparing PA-US images
corrected with rapid vs. complex fluence correction strategies.
In conclusion, the major findings in this work were that PA imaging of endogenous hemoglobin
and exogenous Lipo-JICGs provides noninvasive in vivo assessments of SO2 and cell receptor
expression, respectively. SO2 was shown as a biomarker for disease progression of acute lymphoblastic leukemia, which previously has only been assessed via invasive, single-time-point
measurements with ex vivo and in vivo methods. FRα-Lipo-JICGs were specifically targeted
to SKOV3 ovarian tumors, demonstrating a noninvasive technique to monitor cell receptor expression, which can guide clinicians to more effective treatment schemes targeted to particular
cell markers. Simultaneous PA imaging of these two biomarkers has potential to be translated
clinically with further development and optimization of this molecular imaging platform.
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